<SEC-DOCUMENT>0001104659-26-000209.txt : 20260102
<SEC-HEADER>0001104659-26-000209.hdr.sgml : 20260102
<ACCEPTANCE-DATETIME>20260102161958
ACCESSION NUMBER:		0001104659-26-000209
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20251229
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Termination of a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260102
DATE AS OF CHANGE:		20260102

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Zura Bio Ltd
		CENTRAL INDEX KEY:			0001855644
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40598
		FILM NUMBER:		26502643

	BUSINESS ADDRESS:	
		STREET 1:		4225 EXECUTIVE SQUARE
		STREET 2:		SUITE 600
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		858-247-0520

	MAIL ADDRESS:	
		STREET 1:		4225 EXECUTIVE SQUARE
		STREET 2:		SUITE 600
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	JATT Acquisition Corp
		DATE OF NAME CHANGE:	20210407
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2531128d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:zura="http://zurabio.com/20251229">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_zura_zurabio.com_20251229 -->
<!-- Field: Set; Name: xdx; ID: xdx_04F_20251229_20251229 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DEntityCentralIndexKey_0001855644 -->
<!-- Field: Set; Name: xdx; ID: xdx_072_SO_T%2D%2D\DeptFiles%2DiXBRL 8%2DK Covers Templates\+++%2DROOT%2DElement%2D+++\DocumentInformationLineItems.xdxs -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-12-29" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-12-29" id="Fact000004" name="dei:EntityCentralIndexKey">0001855644</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="zura-20251229.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-12-29">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-12-29</xbrli:startDate>
        <xbrli:endDate>2025-12-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="text-align: center; margin-top: 0; margin-bottom: 0"></p>
<p style="text-align: center; margin-top: 0; margin-bottom: 0"><span id="xdx_912_eus-gaap--WarrantMember_zRC8tlOXyvI9" style="display: none; visibility: hidden">Warrants [Member]</span></p>

<!-- Field: Rule-Page --><div style="text-align: center; margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; text-align: center; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 10pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160; </p>

<p style="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="text-transform: uppercase"><b>Form
</b></span><b><span id="xdx_90A_edei--DocumentType_c20251229__20251229_zG3JYSGE3ARj"><ix:nonNumeric contextRef="AsOf2025-12-29" id="Fact000011" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #212529"><span style="text-transform: uppercase"><b>Current
Report</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt; text-transform: uppercase"><b>Pursuant
to Section</b></span><b> <span style="text-transform: uppercase; color: #212529">13 </span></b><b><span style="font-size: 10pt; text-transform: uppercase">or
</span></b><b><span style="text-transform: uppercase; color: #212529">15(</span></b><b><span style="font-size: 10pt; text-transform: uppercase">d)</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="font-size: 10pt; text-transform: uppercase">of the Securities Exchange Act of</span></b><b> <span style="text-transform: uppercase; color: #212529">1934</span></b></p>

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #212529"> <b><span id="xdx_906_edei--DocumentPeriodEndDate_c20251229__20251229_zrBZb7N69mb5"><ix:nonNumeric contextRef="AsOf2025-12-29" format="ixt:datemonthdayyearen" id="Fact000012" name="dei:DocumentPeriodEndDate">December 29, 2025</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #212529"><span><b>Date of Report (Date of earliest event reported)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #212529"><span>&#160;</span></p>



<p style="text-align: center; margin-top: 0; margin-bottom: 0"></p>

<p style="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span id="xdx_903_edei--EntityRegistrantName_c20251229__20251229_zY2GH9htJvCb"><ix:nonNumeric contextRef="AsOf2025-12-29" id="Fact000013" name="dei:EntityRegistrantName">Zura Bio Limited</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_904_edei--EntityIncorporationStateCountryCode_c20251229__20251229_ziIqoTuSDEPf"><ix:nonNumeric contextRef="AsOf2025-12-29" format="ixt-sec:edgarprovcountryen" id="Fact000014" name="dei:EntityIncorporationStateCountryCode">Cayman Islands</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center; width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_905_edei--EntityFileNumber_c20251229__20251229_zr0N8dnbeJoj"><ix:nonNumeric contextRef="AsOf2025-12-29" id="Fact000015" name="dei:EntityFileNumber">001-40598</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center; width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_906_edei--EntityTaxIdentificationNumber_c20251229__20251229_zPqQoCwSsOB1"><ix:nonNumeric contextRef="AsOf2025-12-29" id="Fact000016" name="dei:EntityTaxIdentificationNumber">98-1725736</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt"><b>(State or other jurisdiction of <br/>
incorporation)</b></span></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td style="text-align: center"><b>(Commission <br/>
File Number)</b></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td style="text-align: center"><span style="font-size: 10pt"><b>(I.R.S. Employer <br/>
    Identification No.)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #212529"><b><span id="xdx_906_edei--EntityAddressAddressLine1_c20251229__20251229_zCj5U23C5K66"><ix:nonNumeric contextRef="AsOf2025-12-29" id="Fact000017" name="dei:EntityAddressAddressLine1">1489 W. Warm Springs Rd.</ix:nonNumeric></span> <span id="xdx_903_edei--EntityAddressAddressLine2_c20251229__20251229_zWg2byBqcNNj"><ix:nonNumeric contextRef="AsOf2025-12-29" id="Fact000018" name="dei:EntityAddressAddressLine2">#110</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #212529"><b><span id="xdx_909_edei--EntityAddressCityOrTown_c20251229__20251229_zJ4q0jiYO7ji"><ix:nonNumeric contextRef="AsOf2025-12-29" id="Fact000019" name="dei:EntityAddressCityOrTown">Henderson</ix:nonNumeric></span>, <span id="xdx_908_edei--EntityAddressStateOrProvince_c20251229__20251229_z2Be2YIlPoZ4"><ix:nonNumeric contextRef="AsOf2025-12-29" id="Fact000020" name="dei:EntityAddressStateOrProvince">NV</ix:nonNumeric></span> <span id="xdx_90F_edei--EntityAddressPostalZipCode_c20251229__20251229_z570ulQ10Gx3"><ix:nonNumeric contextRef="AsOf2025-12-29" id="Fact000021" name="dei:EntityAddressPostalZipCode">89014</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #212529">&#160;<b>(Address of principal
executive offices,<br/>
including zip code)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #212529"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #212529"><b>(<span id="xdx_904_edei--CityAreaCode_c20251229__20251229_zAh21SM66wE5"><ix:nonNumeric contextRef="AsOf2025-12-29" id="Fact000022" name="dei:CityAreaCode">702</ix:nonNumeric></span>) <span id="xdx_901_edei--LocalPhoneNumber_c20251229__20251229_zd9HmG2DTUnl"><ix:nonNumeric contextRef="AsOf2025-12-29" id="Fact000023" name="dei:LocalPhoneNumber">825-9872</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #212529">&#160;<b>(Registrant&#8217;s telephone
number, including area code)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #212529"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #212529"><b>(Former name or former address,
if changed since last report)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #212529"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.3in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_90F_edei--WrittenCommunications_c20251229__20251229_zeK5x9RVZixi"><ix:nonNumeric contextRef="AsOf2025-12-29" format="ixt:booleanfalse" id="Fact000024" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.3in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_901_edei--SolicitingMaterial_c20251229__20251229_za9qY5lPnpt1"><ix:nonNumeric contextRef="AsOf2025-12-29" format="ixt:booleanfalse" id="Fact000025" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.3in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_90B_edei--PreCommencementTenderOffer_c20251229__20251229_zKwnXxYWPgx9"><ix:nonNumeric contextRef="AsOf2025-12-29" format="ixt:booleanfalse" id="Fact000026" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.3in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_904_edei--PreCommencementIssuerTenderOffer_c20251229__20251229_zQ3kRVyCdWlc"><ix:nonNumeric contextRef="AsOf2025-12-29" format="ixt:booleanfalse" id="Fact000027" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 44%; padding-top: 1.05pt; padding-right: 1.05pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="width: 2%; padding-top: 1.05pt; padding-right: 1.05pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 18%; padding-top: 1.05pt; padding-right: 1.05pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading<br/>
</b></span><b><span style="font-size: 10pt">Symbol(s)</span></b></td>
    <td style="width: 2%; padding-top: 1.05pt; padding-right: 1.05pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 34%; padding-top: 1.05pt; padding-right: 1.05pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which<br/>
 registered</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 1.3pt; padding-right: 1.3pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--Security12bTitle_c20251229__20251229_zdo4SzKDgyk9"><ix:nonNumeric contextRef="AsOf2025-12-29" id="Fact000028" name="dei:Security12bTitle">Class A Ordinary Shares, par value $0.0001 per share</ix:nonNumeric></span></b></span></td>
    <td style="padding-top: 1.3pt; padding-right: 1.3pt">&#160;</td>
    <td style="padding-top: 1.3pt; padding-right: 1.3pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--TradingSymbol_c20251229__20251229_z5Nyr7jgO06d"><ix:nonNumeric contextRef="AsOf2025-12-29" id="Fact000029" name="dei:TradingSymbol">ZURA</ix:nonNumeric></span></b></span></td>
    <td style="padding-top: 1.3pt; padding-right: 1.3pt">&#160;</td>
    <td style="padding-top: 1.3pt; padding-right: 1.3pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--SecurityExchangeName_c20251229__20251229_zJ1trIy1t0of"><ix:nonNumeric contextRef="AsOf2025-12-29" format="ixt-sec:exchnameen" id="Fact000030" name="dei:SecurityExchangeName">The Nasdaq Stock Market</ix:nonNumeric></span></b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in; text-align: justify; color: #212529">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; color: #212529">Emerging growth company <span style="font-family: Wingdings"><span id="xdx_908_edei--EntityEmergingGrowthCompany_c20251229__20251229_zTvka1iLqnxi"><ix:nonNumeric contextRef="AsOf2025-12-29" format="ixt:booleantrue" id="Fact000031" name="dei:EntityEmergingGrowthCompany">x</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in; text-align: justify; color: #212529">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings"><span id="xdx_909_edei--EntityExTransitionPeriod_c20251229__20251229_zhBtDKC6TD7h"><ix:nonNumeric contextRef="AsOf2025-12-29" format="ixt:booleanfalse" id="Fact000032" name="dei:EntityExTransitionPeriod">&#168;</ix:nonNumeric></span></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"><b>Item 1.01.</b></td><td style="text-align: justify"><b>Entry into a Material Definitive Agreement. </b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 29, 2025, Zura Bio Limited (the &#8220;Company&#8221;)
and its subsidiaries, Athanor Capital, an exempted company incorporated under the laws of the Cayman Islands with limited liability (&#8220;Athanor&#8221;),
Stone Peach Properties LLC, a Georgia limited liability company (&#8220;Stone Peach&#8221;) and its principals, and BAFFX17, a limited
company incorporated under the laws of England and Wales (&#8220;BAFFX17&#8221;) and its principals, entered into several agreements which
were determined to be more commercially advantageous to the Company. Specifically, the new agreements (1) terminated or voided all previous
agreements between the Company and its subsidiaries, on the one hand, and Stone Peach or BAFFX17, on the other hand, including the extinguishment
of any and all rights or claims Stone Peach or BAFFX17 may have under all previous agreements; (2) provided general releases from Stone
Peach or BAFFX17, respectively, of the Company, together with its affiliates, of any and all actual or potential claims under the previous
agreements; and (3) established new commercial terms with Athanor (in its capacity as acquiror of the rights previously held by Stone
Peach) which the Company believes are more commercially advantageous to the Company than the previous agreements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Athanor Letter Agreement </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 29, 2025, the Company and Athanor, in its capacity as acquiror of all of the rights, title and interest previously held by Stone
Peach in and to (i) that certain letter agreement by and between Stone Peach, the Company and the Company&#8217;s consolidated subsidiary,
Z33 Bio Inc. (&#8220;Z33&#8221;), dated December 8, 2022, as amended by letter agreement dated November 21, 2023 (the &#8220;Z33 Letter
Agreement&#8221;) and (ii)&#160;that certain letter agreement by and between Stone Peach, the Company and ZB17 LLC (&#8220;ZB17&#8221;),
dated April 24, 2023, as amended by letter agreement dated November 21, 2023 (the &#8220;ZB17 Letter Agreement&#8221; and, together with
the Z33 Letter Agreement, the &#8220;Letter Agreements&#8221;), mutually agreed to terminate the Letter Agreements. In connection with
the parties&#8217; termination of the Z33 Letter Agreement pursuant to the Athanor Agreement (as defined below), the parties&#8217; respective
call and put rights relating to Z33&#8217;s series&#160;seed preferred shares were extinguished. In connection with the parties&#8217;
termination of the ZB17 Letter Agreement pursuant to the Athanor Agreement, Athanor&#8217;s right to purchase 4.99% of the fully diluted
equity of ZB17 and the Company&#8217;s annual payment obligation to Athanor were extinguished.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 29, 2025, in connection with the termination of the Letter Agreements, the Company entered into a letter agreement with Athanor
(the &#8220;Athanor Agreement&#8221;), pursuant to which the Company agreed to issue to Athanor </span>8,657,402 Class A ordinary shares,
of par value US$0.0001 each, of the Company (the &#8220;Athanor Shares&#8221;). Athanor is also entitled to piggyback registration rights
pursuant to which Athanor has the right to include Athanor Shares in certain registered offerings by the Company or if the Company proposes
to file a registration statement under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), with respect to the
registration of equity securities, as set forth in the Athanor Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, pursuant to the terms of the Athanor Agreement, the Company agreed to pay Athanor an upfront fee in an amount equal to $7,325,000
within thirty days of execution of the Athanor Agreement and a one-time milestone payment in the amount of $25,000,000 after the occurrence
of the earliest of the following events: (i) the Company or ZB17 undergoes a Change of Control (as defined in the Athanor Agreement),
(ii) the consummation by the Company or ZB17 of a sale of assets resulting in net proceeds in excess of $500,000,000, or (iii) First Indication
Regulatory Approval (as defined in the Athanor Agreement). In addition, pursuant to the terms of the Athanor Agreement, the Company agreed
to pay an amount equal to 2% of Net Sales (as defined in the Athanor Agreement) for the Product (as defined in the Athanor Agreement)
to the extent such Net Sales (collectively, the &#8220;Net Sales Payments&#8221;) are the subject of a royalty payment under </span>that
certain license agreement dated as of April 26, 2023, by and between ZB17 LLC and Eli Lilly and Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Athanor Agreement contains representations,
warranties and covenants by the parties in addition to the terms described above and shall remain in effect on a country-by-country basis
until the expiration of the obligation to pay the Net Sales Payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For additional information relating to the Letter
Agreements, refer to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 and other filings with
the Securities and Exchange Commission. The foregoing description of the Athanor Agreement is only a summary, does not purport to be complete
and is qualified in its entirety by reference to the full text of the Athanor Agreement, a copy of which is filed as Exhibit 10.1 to this
Current Report on Form 8-K and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Stone Peach Settlement and Release Agreement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the termination of the Letter Agreements, on December
29, 2025, the Company and Stone Peach, Baljit Lehal and Kanwarjeet &#8220;Shawn&#8221; Tucker (the &#8220;Stone Peach Parties&#8221;)
entered into a Settlement and Release Agreement (the &#8220;Stone Peach Settlement Agreement&#8221;). Pursuant to the Stone Peach Settlement
Agreement, the Stone Peach Parties acknowledged that, as between the Company and any of the Stone Peach Parties, each of (i) the Letter
Agreements, (ii) that certain Z33 Founder Issuance Agreement, dated December 8, 2022, between Z33 and Stone Peach, (iii) that certain
Series Seed Preferred Stock Investment Agreement, dated December 8, 2022, between the Company and Stone Peach and (iv) that certain Confidentiality
and Non-Circumvention Agreement dated December 13, 2022, between the Company and Stone Peach (such agreements, the &#8220;Stone Peach
Agreements&#8221;) are terminated and therefore rendered null and void, and unenforceable in part or in whole by any of the Stone Peach
Parties. In addition, pursuant to the Stone Peach Settlement Agreement, the Stone Peach Parties provided a general release of the Company
and its affiliates, together with the Company&#8217;s predecessors, successors, and assigns and past, present and future officers, directors,
shareholders, members, partners, attorneys, agents, employees, managers, representatives, assigns and successors in interest from and
against any and all claims under the Stone Peach Agreements along with any other complaints, claims, causes of action, rights or damages
which the Stone Peach Parties have or may have had against the Company or any of its affiliates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing description of the Stone Peach Settlement
Agreement is only a summary, does not purport to be complete and is qualified in its entirety by reference to the full text of the Stone
Peach Settlement Agreement, a copy of which is filed as Exhibit 10.2 to this Current Report on Form 8-K and is incorporated herein by
reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>BAFFX17 Settlement and Release Agreement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 29, 2025, the Company and BAFFX17, Asim Mohammed and Lahmber
Singh (the &#8220;BAFFX17 Parties&#8221;) entered into a Settlement and Release Agreement (the &#8220;BAFFX17 Settlement Agreement&#8221;).
Pursuant to the BAFFX17 Settlement Agreement, the Company and the BAFFX17 Parties agreed and acknowledged that a certain letter agreement
by and between BAFFX17 and the Company dated April 25, 2023, as amended by letter agreement dated December 18, 2023 (the &#8220;BAFFX17
Agreements&#8221;) are terminated and therefore rendered null and void and unenforceable in part or in whole by any BAFFX17 Party. In
addition, pursuant to the BAFFX17 Settlement Agreement, the BAFFX17 Parties provided a general release of the Company and its affiliates,
together with the Company&#8217;s predecessors, successors, and assigns and past, present and future officers, directors, shareholders,
members, partners, attorneys, agents, employees, managers, representatives, assigns and successors in interest from and against any and
all claims under the BAFFX17 Agreements along with any other complaints, claims, causes of action, rights or damages which the BAFFX17
Parties have or may have had against the Company or any of its affiliates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing description of the BAFFX17 Settlement
Agreement is only a summary, does not purport to be complete and is qualified in its entirety by reference to the full text of the BAFFX17
Settlement Agreement, a copy of which is filed as Exhibit 10.3 to this Current Report on Form 8-K and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"><b>Item 1.02.</b></td><td style="text-align: justify"><b>Termination of a Material Definitive Agreement.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information set forth above in&#160;Item 1.01&#160;&#8220;Entry
into a Material Definitive Agreement&#8221; of this Current Report on Form 8-K relating to the termination of the Letter Agreements is
incorporated by reference into this Item 1.02.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"><b>Item 3.02.</b></td><td style="text-align: justify"><b>Unregistered Sales of Equity Securities.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information set forth above in&#160;Item 1.01&#160;&#8220;Entry
into a Material Definitive Agreement&#8221; of this Current Report on Form 8-K relating to the issuance of the Athanor Shares pursuant
to the Athanor Agreement is incorporated by reference into this Item 3.02. The Athanor Shares were issued&#160;in reliance on&#160;the
exemption from registration requirements provided by Section 4(a)(2) of the&#160;Securities Act and/or&#160;Regulation D&#160;promulgated
thereunder as a transaction by an issuer not involving a public offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"><b>Item 8.01</b></td><td style="text-align: justify"><b>Other Events.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As previously reported in the Company&#8217;s
Quarterly Reports on Form 10-Q for the quarters ended June 30, 2025 and September 30, 2025, the Audit Committee of the Board of Directors
formed the Audit Subcommittee, comprised solely of disinterested and independent directors, to review the Company&#8217;s agreements and
relationships with Stone Peach and BAFFX17, among other matters. The Audit Subcommittee was assisted by independent legal counsel and
a third-party due diligence firm. The Audit Subcommittee&#8217;s internal review is complete, and the results are discussed below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Through legal counsel, the Audit Subcommittee engaged in extensive
fact finding, including reviewing relevant documents and communications. Following a detailed review of this information, and based on
the advice of independent legal counsel, the Audit Subcommittee determined (1) that it was in the best interests of the Company and its
shareholders to replace the Stone Peach Agreements with the more commercially advantageous Athanor Agreement and (2) to terminate or void
the agreements between the Company and its subsidiaries, on the one hand, and Stone Peach or BAFFX17, on the other hand. Consistent with
the determination of the Audit Subcommittee, the Company negotiated, with the assistance of management and legal counsel, the Athanor
Agreement as well as the Stone Peach Settlement Agreement and the BAFFX17 Settlement Agreement, which terminated all outstanding agreements
between the parties and, in the case of the settlement agreements, contain broad releases of claims against the Company, its subsidiaries
and affiliates by Stone Peach, BAFFX17 and their respective principals. The Athanor Agreement, the Stone Peach Settlement Agreement and
the BAFFX17 Settlement Agreement were approved by the Audit Subcommittee and the Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The internal review found no issue with the Company&#8217;s
agreements and relationships with Stone Peach and BAFFX17 that had an impact on the Company&#8217;s financial results under accounting
principles generally accepted in the United States of America or on the financial statements included in the Company&#8217;s previously
filed quarterly or annual reports. Additionally, the internal review found no instances of misconduct by the Company&#8217;s current employees
relating to the agreements or relationships. The internal review also included an analysis of the Company&#8217;s internal controls over
financial reporting and disclosure controls and procedures, and as part of the Company&#8217;s process of continuous improvement, the
Company plans to implement certain additional controls and procedures, which are not expected to materially affect the Company&#8217;s
existing controls and procedures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: left"><b>Item 9.01 </b></td><td style="text-align: justify">Financial Statements and
Exhibits.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) Exhibits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 6%; text-align: justify"><a href="tm2531128d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1*</span></a></td>
    <td style="width: 94%; text-align: justify"><a href="tm2531128d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Letter Agreement, dated </span>December 29, 2025, by and between Zura Bio Limited and Athanor Capital</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><a href="tm2531128d1_ex10-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></a></td>
    <td style="text-align: justify"><a href="tm2531128d1_ex10-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Settlement and Release Agreement, dated </span>December 29, 2025, by and between Zura Bio Limited and the Stone Peach Parties</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><a href="tm2531128d1_ex10-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></a></td>
    <td style="text-align: justify"><a href="tm2531128d1_ex10-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Settlement and Release Agreement, dated </span>December 29, 2025, by and between Zura Bio Limited and the BAFFX17 Parties</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* Portions of this exhibit have been&#160;redacted&#160;in accordance
with&#160;Item 601(b)(10)(iv) of&#160;Regulation S-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><b>SIGNATURES</b></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2" style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZURA BIO LIMITED</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: January 2, 2026 </span></td>
    <td style="width: 3%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; width: 47%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Kim Davis</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kim Davis</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim Chief Executive Officer, Chief Operating Officer, Chief Legal Officer and Corporate Secretary</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5lpoGi9BHi4pYpRQRX4NdJdhmyyb+9Eje0tgiLgvLMvPNCDERa1qZBhlOi6qAA7Zdoz1ChRdktGcMjnyzzSDcCq/GedbWD+8PzCkwGJg0VkoHYbA+jMM6AzmbyvlUzSCRmUyh3Inoq+dkL6ZG641uQNsaSqaODXrN/Zhw0C+y1PZD1RHZGbIZJLEc5TcomSjY00M/iW8OiiIX0WSYSKyZ7l1wLV8e7ZeEZYNtqHMj/d/oAwR5Sok= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>tm2531128d1_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt"><B>Exhibit 10.1&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>CERTAIN IDENTIFIED
INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT&#8239;BECAUSE IT IS BOTH (I)&#8239;NOT MATERIAL AND (II)&#8239;THE TYPE THAT THE REGISTRANT
NORMALLY TREATS AS PRIVATE AND CONFIDENTIAL. OMISSIONS ARE IDENTIFIED AS [***].</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>dated as of December&nbsp;29,
2025</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>by and between</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ZURA BIO LIMITED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>and</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ATHANOR CAPITAL</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">This
Agreement (this &ldquo;<B>Agreement</B>&rdquo;), dated as of December&nbsp;29, 2025 (the &ldquo;<B>Effective Date</B>&rdquo;), is made
by and between Athanor Capital, a Cayman Islands exempted company (&ldquo;<B>Athanor</B>&rdquo;), and Zura Bio Limited, a Cayman Islands
exempted company (&ldquo;<B>Zura Bio</B>&rdquo;). Zura Bio and Athanor are sometimes referred to herein individually as a &ldquo;<B>Party</B>&rdquo;
and collectively as the &ldquo;<B>Parties</B>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>RECITALS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">In
connection with the Parties&rsquo; termination of the Letter Agreements (as defined below) and in consideration of the foregoing premises
and the mutual promises, covenants and conditions contained in this Agreement, and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged and agreed, the Parties agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;1</B></FONT><B><FONT STYLE="font-size: 10pt"><BR>
DEFINITIONS</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">As
used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this Article&nbsp;1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&ldquo;<B>Adverse
Disclosure</B>&rdquo; shall mean any public disclosure of material non-public information, which disclosure, after consultation with
legal counsel to Zura Bio, in the good faith judgment of the Chief Executive Officer or Chief Financial Officer of Zura Bio or the board
of directors of Zura Bio, (i)&nbsp;would be required to be made in any Registration Statement or Prospectus in order for the applicable
Registration Statement or Prospectus not to contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements contained therein (in the case of any prospectus and any preliminary prospectus, in the light of the circumstances
under which they were made) not misleading, (ii)&nbsp;would not be required to be made at such time if the Registration Statement were
not being filed, declared effective or used, as the case may be, and (iii)&nbsp;Zura Bio has a <I>bona fide</I> business purpose for
not making such information public.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&ldquo;<B>Affiliate</B>&rdquo;
means any Person that, directly or indirectly, through one or more intermediaries, controls, is controlled by, is controlling or is under
common control with, such person, and (a)&nbsp;in the case of a natural person, shall include, without limitation, such person&rsquo;s
spouse, parents, children, siblings, mother-in-law and father-in-law and brothers and sisters-in-law, whether by blood, marriage or adoption
or anyone residing in such person&rsquo;s home, a trust for the benefit of any of the foregoing, a company, partnership or any natural
person or entity wholly or jointly owned by any of the foregoing and (b)&nbsp;in the case of an entity, shall include a partnership,
a corporation or any natural person or entity which directly, or indirectly through one or more intermediaries, controls, is controlled
by, or is under common control with, such entity. For purposes of this definition, &ldquo;<B>control</B>&rdquo; (including, with correlative
meanings, &ldquo;<B>controlled by,</B>&rdquo; &ldquo;<B>controlling</B>&rdquo; and &ldquo;<B>under common control with</B>&rdquo;) means
(a)&nbsp;possession, direct or indirect, of the power to direct or cause direction of the management or policies of an entity (whether
through ownership of securities or other ownership interests, by contract or otherwise), or (b)&nbsp;&ldquo;<B>Beneficial Ownership</B>&rdquo;
(as calculated in accordance with Section&nbsp;13(d)&nbsp;of the Securities Exchange Act of 1934 and the rules&nbsp;and regulations promulgated
thereunder) of more than 50% (or the maximum ownership interest permitted by Applicable Law) of the voting securities or other ownership
or general partnership interest (whether directly or pursuant to any option, warrant or other similar arrangement) or other comparable
equity interests of an entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&ldquo;<B>Applicable
Law</B>&rdquo; means any applicable United States federal, state or local, or foreign or multinational law (including data protection
and privacy laws), statute, standard, ordinance, code, rule, regulation, resolution or promulgation, or any order, writ, judgment, injunction,
decree, stipulation, ruling, determination or award entered by or with any Governmental Authority, or any license, franchise, permit
or similar right granted under any of the foregoing, or any similar provision having the force or effect of law. For the avoidance of
doubt, any specific references to any Applicable Law or any portion thereof shall be deemed to include all then-current amendments thereto
or any replacement or successor law, statute, standard, ordinance, code, rule, regulation, resolution, order, writ, judgment, injunction,
decree, stipulation, ruling or determination thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&ldquo;<B>Business
Day</B>&rdquo; means a day other than a Saturday, Sunday, or bank or other public holiday in New York, New York,&nbsp;Indianapolis,&nbsp;Indiana,
United States, the Cayman Islands or London, United Kingdom.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&ldquo;<B>Calendar
Quarter</B>&rdquo; means each three (3)-month period commencing January&nbsp;1, April&nbsp;1, July&nbsp;1 or October&nbsp;1 of any year;
provided, however, that (a)&nbsp;the first Calendar Quarter of the Term shall extend from the Effective Date to the end of the first
full Calendar Quarter thereafter and (b)&nbsp;the last Calendar Quarter of the Term shall end upon the expiration or termination of this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&ldquo;<B>Change
of Control</B>&rdquo; means, with respect to Zura Bio or ZB17 LLC, a Delaware limited liability company (&ldquo;<B>ZB17</B>&rdquo;),
(a)&nbsp;a merger or consolidation or similar transaction of Zura Bio or ZB17, respectively, with a Third Party that results (i)&nbsp;in
the voting securities of such Zura Bio or ZB17, respectively, outstanding immediately prior thereto, or any securities into which such
voting securities have been converted or exchanged, ceasing to represent more than fifty percent (50%) of the combined voting power of
the surviving entity or the parent of the surviving entity immediately after such merger or consolidation or (ii)&nbsp;in the members
of the board of directors of Zura Bio or ZB17, respectively, immediately prior to such transaction constituting less than a majority
of the members of the board of directors of Zura Bio or ZB17, respectively, immediately following such transaction, or (b)&nbsp;a transaction
or series of related transactions in which a Third Party, together with its Affiliates, (i)&nbsp;becomes the Beneficial Owner of more
than fifty percent (50%) of the combined voting power of the outstanding securities of Zura Bio or ZB17, respectively, or (ii)&nbsp;has
the power, directly or indirectly, to elect a majority of the members of Zura Bio&rsquo;s or ZB17&rsquo;s board of directors, or similar
governing body, but in each case (a)&nbsp;and (b), excluding any consolidation or merger effected exclusively to change the domicile
of Zura Bio or ZB17, respectively, any transaction or series of transactions effected principally for &acy; bona fide financing transaction,
and an offering of shares or stock sale to underwriters in a public offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&ldquo;<B>Class&nbsp;A
Shares</B>&rdquo; shall mean the class A ordinary shares, of par value US$0.0001 each, of Zura Bio.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&ldquo;<B>Commission</B>&rdquo;
shall mean the U.S. Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&ldquo;<B>Designated
Officer</B>&rdquo; means a representative appointed by a Party for purposes of dispute resolution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&ldquo;<B>Dollar</B>&rdquo;
or &ldquo;<B>$</B>&rdquo; means the legal tender of the United States of America.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&ldquo;<B>Encumbrance</B>&rdquo;
means any lien, pledge, hypothecation, charge, mortgage, security interest, encumbrance, claim, infringement, interference, option, right
of first refusal, co-sale, tag along or drag along right, preemptive right, community property interest or restriction of any nature
(including any restriction on the voting of any security, any restriction on the transfer of any security or other asset, any restriction
on the receipt of any income derived from any asset, any restriction on the use of any asset and any restriction on the possession, exercise
or transfer of any other attribute of ownership of any asset.)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&ldquo;<B>First
Indication Regulatory Approval</B>&rdquo; means, with respect to a specified jurisdiction, the receipt of Regulatory Approval in such
jurisdiction for the Product for any Indication (being an Indication for which no Regulatory Approval has previously been received for
such Product in such jurisdiction).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&ldquo;<B>Force
Majeure</B>&rdquo; means any circumstances whatsoever which are not within the reasonable control of the Party affected thereby, including
any such act of God, war, act of terrorism, pandemic, insurrection, riot, strike or labor dispute, shortage of materials, fire, explosion,
flood, government requisition or allocation, breakdown of or damage to plant, equipment or facilities, interruption or delay in transportation,
fuel supplies or electrical power, embargo, boycott, order, or act of civil, military, or other Governmental Authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.14&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&ldquo;<B>Governmental
Authority</B>&rdquo; means any United States federal, state or local, or any foreign government or political subdivision thereof, or
any multinational organization or authority, or any authority, agency or commission entitled to exercise any administrative, executive,
judicial, legislative, police, regulatory or taxing authority or power, any court or tribunal (or any department, bureau or division
thereof), or any governmental arbitrator or arbitral body. For clarity, any Regulatory Authority shall be a Governmental Authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.15&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&ldquo;<B>Indication</B>&rdquo;
means any disease or condition that a product can be used to treat or prevent, which use is the subject of a separate Regulatory Approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.16&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&ldquo;<B>Letter
Agreements</B>&rdquo; means, collectively, (i)&nbsp;that certain letter agreement by and among Stone Peach Properties LLC, a Georgia
limited liability company (&ldquo;<B>Stone Peach</B>&rdquo;), Zura Bio, and Z33 Bio Inc., dated December&nbsp;8, 2022, as amended by
letter agreement dated November&nbsp;21, 2023; and (ii)&nbsp;that certain letter agreement by and among Stone Peach, Zura Bio, and ZB17,
dated April&nbsp;24, 2023, as amended by letter agreement dated November&nbsp;21, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.17&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&ldquo;<B>Lilly</B>&rdquo;
means Eli Lilly and Company, an Indiana corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.18&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&ldquo;<B>Lilly
Agreement</B>&rdquo; means that certain License, Development and Commercialization Agreement dated as of April&nbsp;26, 2023 by and between
Lilly and ZB17.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.19&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&ldquo;<B>Maximum
Number of Securities</B>&rdquo; means the maximum dollar amount or maximum number of securities that can be sold in the Underwritten
Offering without adversely affecting the proposed offering price, the timing, the distribution method or the probability of success of
such offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.20&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&ldquo;<B>Misstatement</B>&rdquo;
shall mean an untrue statement of a material fact or an omission to state a material fact required to be stated in a Registration Statement
or Prospectus or necessary to make the statements in a Registration Statement or Prospectus (in the case of a Prospectus, in the light
of the circumstances under which they were made) not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.21&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&ldquo;<B>Net
Sales</B>&rdquo; has the meaning given to such term in the Lilly Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.22&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&ldquo;<B>Person</B>&rdquo;
means any individual, firm, corporation, partnership, limited liability company, trust, business trust, joint venture, Governmental Authority,
association or other entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.23&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&ldquo;<B>Pricing
Approval</B>&rdquo; means, with respect to any country where a Governmental Authority authorizes reimbursement or access, or approves
or determines pricing, for pharmaceutical products, receipt (or, if required to make such authorization, approval of determination effective
publication) of such reimbursement or access authorization or pricing approval or determination (as the case may be).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.24&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&ldquo;<B>Product</B>&rdquo;
means tibulizumab (ZB-106).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.25&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&ldquo;<B>Prospectus</B>&rdquo;
shall mean the prospectus included in any Registration Statement, as supplemented by any and all prospectus supplements and as amended
by any and all post-effective amendments and including all material incorporated by reference in such prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.26&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&ldquo;<B>Registrable
Security</B>&rdquo; shall mean (a)&nbsp;the Athanor Shares, (b)&nbsp;any other equity security of Zura Bio issued or issuable with respect
to the Athanor Shares by way of a share capitalization or share split or in connection with a combination of shares, recapitalization,
merger, consolidation or reorganization; <U>provided</U>, <U>however</U>, that, as to any particular Registrable Security, such securities
shall cease to be Registrable Securities when: (i)&nbsp;a Registration Statement with respect to the sale of such securities shall have
become effective under the Securities Act and such securities shall have been sold, transferred, disposed of or exchanged in accordance
with such Registration Statement by Athanor; (ii)&nbsp;such securities shall have been otherwise sold or transferred; (iii)&nbsp;such
securities shall have ceased to be outstanding; and (iv)&nbsp;such securities may be sold without registration pursuant to Rule&nbsp;144
(but without the requirement to comply with any limitations).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.27&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&ldquo;<B>Registration
Statement</B>&rdquo; shall mean any registration statement filed by Zura Bio with the Commission that covers the Registrable Securities
pursuant to the provisions of this Agreement, including the Prospectus included in such registration statement, amendments (including
post-effective amendments) and supplements to such registration statement, and all exhibits to and all material incorporated by reference
in such registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.28&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&ldquo;<B>Regulatory
Approval</B>&rdquo; means, with respect to a Product in any regulatory jurisdiction for a given Indication, approval from the applicable
Regulatory Authority permitting the manufacture, distribution, use and sale of such Product in such regulatory jurisdiction for such
Indication in accordance with Applicable Law, including any Pricing Approvals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.29&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&ldquo;<B>Regulatory
Authority</B>&rdquo; means, in a particular country or regulatory jurisdiction, any applicable Governmental Authority involved in granting
Regulatory Approval or, to the extent required in such country or regulatory jurisdiction, Pricing Approval of a Product in such country
or regulatory jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.30&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&ldquo;<B>Related
Parties</B>&rdquo; means, with respect to Zura Bio, its (i)&nbsp;Affiliates and (ii)&nbsp;sublicensees of the commercial rights granted
to Zura Bio under the Lilly Agreement (excluding distributors).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.31&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&ldquo;<B>Securities
Act</B>&rdquo; shall mean the U.S. Securities Act of 1933, as amended from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.32&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&ldquo;<B>Stone
Peach Assignment</B>&rdquo; means the acquisition by Athanor, pursuant to the terms of Athanor&rsquo;s September&nbsp;22, 2025 agreement
with Stone Peach, of (i)&nbsp;all of Stone Peach&rsquo;s rights under the Letter Agreements and (ii)&nbsp;the Z33 Bio Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.33&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&ldquo;<B>Subsidiary</B>&rdquo;
means, with respect to any Person, any corporation, partnership, limited liability company, association or other business entity of which,
(a)&nbsp;if a corporation, a majority of the total voting power of shares of stock entitled (irrespective of whether, at the time, stock
of any other class or classes of such corporation shall have or might have voting power by reason of the happening of any contingency)
to vote in the election of directors, managers or trustees thereof is at the time owned or controlled, directly or indirectly, by that
Person or one or more of the other Subsidiaries of that Person or a combination thereof, or (b)&nbsp;if a partnership, limited liability
company, association or other business entity, either (i)&nbsp;a majority of the partnership or other similar ownership interest thereof
is at the time owned or controlled, directly or indirectly, by that Person or one or more Subsidiaries of that Person or a combination
thereof, or (ii)&nbsp;such Person is a general partner, managing member or managing director of such partnership, limited liability company,
association or other entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.34&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&ldquo;<B>Territory</B>&rdquo;
means worldwide.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.35&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&ldquo;<B>Third
Party</B>&rdquo; means any Person other than Athanor, Zura Bio or their respective Affiliates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.36&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&ldquo;<B>Underwriter</B>&rdquo;
shall mean a securities dealer who purchases any Registrable Securities as principal in an Underwritten Offering and not as part of such
dealer&rsquo;s market-making activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.37&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&ldquo;<B>Underwritten
Offering</B>&rdquo; shall mean a Registration in which securities of Zura Bio are sold to an Underwriter in a firm commitment underwriting
for distribution to the public.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.38&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&ldquo;<B>United
States</B>&rdquo; or &ldquo;<B>U.S.</B>&rdquo; means the United States of America and its possessions and territories.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.39&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&ldquo;<B>Z33
Bio</B>&rdquo; means Z33 Bio Inc., a Delaware corporation and Subsidiary of Zura.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.40&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>&ldquo;<B>Z33
Bio Shares</B>&rdquo; means the 4,900,222 shares of Z33 Bio preferred stock held by Stone Peach prior to the Stone Peach Assignment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;2</B></FONT><B><FONT STYLE="font-size: 10pt"><BR>
EQUITY PROVISIONS</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>2.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Share
Issuance.</B> As of the Effective Date, Zura Bio shall be obligated to issue and, no later than five (5)&nbsp;Business Days after the
Effective Date, Zura Bio shall issue to Athanor 8,657,402 Class&nbsp;A Shares (the &ldquo;<B>Athanor Shares</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>2.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Legends.
</B>The Athanor Shares shall bear legends substantially to the following effect:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">THE
OFFER AND SALE OF THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES
ACT&rdquo;), AND MAY&nbsp;NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">THE SECURITIES REPRESENTED
HEREBY ARE OWNED BY A PERSON, OR PERSONS, WHO MAY&nbsp;BE CONSIDERED AN AFFILIATE FOR PURPOSES OF RULE 144 UNDER THE SECURITIES ACT.
NO TRANSFER OF THESE SECURITIES OR ANY INTEREST THEREIN MAY&nbsp;BE MADE, EXCEPT IN COMPLIANCE WITH THE REQUIREMENTS OF RULE 144 OR PURSUANT
TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL TO THE COMPANY
SATISFACTORY TO THE COMPANY THAT SUCH TRANSFER DOES NOT REQUIRE REGISTRATION UNDER THE SECURITIES ACT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>2.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Z33
Bio Share Transfer.</B> As of the Effective Date, Athanor shall transfer to Zura Bio or its designee the Z33 Bio Shares acquired by Athanor
pursuant to the Stone Peach Assignment, free and clear of all Encumbrances (the &ldquo;<B>Z33 Bio Share Transfer</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>2.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Piggyback
Registration.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>2.4.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Piggyback
Rights</B>. If Zura Bio proposes to conduct a registered offering of, or if Zura Bio proposes to file a Registration Statement under
the Securities Act with respect to the Registration of, equity securities, or securities or other obligations exercisable or exchangeable
for, or convertible into equity securities, for its own account or for the account of shareholders of Zura Bio, other than a Registration
Statement (or any registered offering with respect thereto) (i)&nbsp;filed in connection with any employee share option or other benefit
plan, (ii)&nbsp;for an exchange offer or offering of securities solely to Zura Bio&rsquo;s existing shareholders, (iii)&nbsp;pursuant
to a Registration Statement on Form&nbsp;S-4 (or similar form that relates to a transaction subject to Rule&nbsp;145 under the Securities
Act or any successor rule&nbsp;thereto), (iv)&nbsp;for an offering of debt that is convertible into equity securities of Zura Bio or
(v)&nbsp;for a dividend reinvestment plan, then Zura Bio shall give written notice of such proposed offering to Athanor as soon as practicable
but not less than ten days before the anticipated filing date of such Registration Statement, which notice shall (A)&nbsp;describe the
amount and type of securities to be included in such offering, the intended method(s)&nbsp;of distribution, and the name of the proposed
managing Underwriter or Underwriters, if any, in such offering, and (B)&nbsp;offer to Athanor the opportunity to include in such registered
offering such number of Registrable Securities as Athanor may request in writing within five days after receipt of such written notice
(such Registration, a &ldquo;<B>Piggyback Registration</B>&rdquo;). Subject to <U>Section&nbsp;2.3.2</U> hereof, Zura Bio shall, in good
faith, cause such Registrable Securities to be included in such Piggyback Registration and, if applicable, shall use its commercially
reasonable efforts to cause the managing Underwriter or Underwriters of such Piggyback Registration to permit the Registrable Securities
requested by Athanor pursuant to this <U>Section&nbsp;2.3.1</U> to be included therein on the same terms and conditions as any similar
securities of Zura Bio included in such registered offering and to permit the sale or other disposition of such Registrable Securities
in accordance with the intended method(s)&nbsp;of distribution thereof. The inclusion of the Registrable Securities in a Piggyback Registration
shall be subject to Athanor&rsquo;s agreement to enter into an underwriting agreement in customary form with the Underwriter(s)&nbsp;selected
for such Underwritten Offering by Zura Bio.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>2.4.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Reduction
of Piggyback Registration. </B>If the managing Underwriter or Underwriters in an Underwritten Offering that is to be a Piggyback Registration,
in good faith, advise(s)&nbsp;Zura Bio in writing that the dollar amount or number of Class&nbsp;A Shares or other equity securities
that Zura Bio desires to sell, taken together with (i)&nbsp;the Registrable Securities as to which Registration has been requested by
Athanor pursuant to <U>Section&nbsp;2.3.1</U> and (ii)&nbsp;the number of Class&nbsp;A Shares or other equity securities, if any, as
to which Registration or a registered offering has been requested pursuant to separate written contractual piggy-back registration rights
of persons or entities other than Athanor, exceeds the Maximum Number of Securities, then:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt"><B>(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>if
the Registration or registered offering is undertaken for Zura Bio&rsquo;s account, Zura Bio shall include in any such Registration or
registered offering (A)&nbsp;first, the number of Class&nbsp;A Shares or other equity securities that Zura Bio desires to sell, which
can be sold without exceeding the Maximum Number of Securities; (B)&nbsp;second, to the extent that the Maximum Number of Securities
has not been reached under the foregoing clause (A), the aggregate number of Registrable Securities that Athanor has requested pursuant
to <U>Section&nbsp;2.3.1</U> to be included in such Underwritten Offering and the number of securities, if any, as to which Registration
or a registered offering has been requested pursuant to separate written contractual piggy-back registration rights by persons or entities
other than Athanor, <I>pro rata, </I>based on the respective number of securities that Athanor and each such other holder has requested
be included in such Underwritten Offering and the aggregate number of securities that Athanor and such other holders have requested to
be included in such Underwritten Offering, which can be sold without exceeding the Maximum Number of Securities; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt"><B>(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>if
the Registration or registered offering is pursuant to a request by persons or entities other than Athanor, then Zura Bio shall include
in any such Registration or registered offering (A)&nbsp;first, the number of Shares or other equity securities, if any, of such requesting
persons or entities, other than Athanor, pursuant to separate written contractual piggy-back registration rights, which can be sold without
exceeding the Maximum Number of Securities; (B)&nbsp;second, to the extent that the Maximum Number of Securities has not been reached
under the foregoing clause (A), the aggregate number of Registrable Securities that Athanor has requested pursuant to <U>Section&nbsp;2.3.1</U>
to be included in such Underwritten Offering, which can be sold without exceeding the Maximum Number of Securities; and (C)&nbsp;third,
to the extent that the Maximum Number of Securities has not been reached under the foregoing clauses (A)&nbsp;and (B), the number of
Class&nbsp;A Shares or other equity securities that Zura Bio desires to sell, which can be sold without exceeding the Maximum Number
of Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>2.4.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Piggyback
Registration Withdrawal</B>. Athanor shall have the right to withdraw from a Piggyback Registration for any or no reason whatsoever upon
written notification to Zura Bio and the Underwriter or Underwriters (if any) of its intention to withdraw from such Piggyback Registration
prior to the effectiveness of the Registration Statement filed with the Commission with respect to such Piggyback Registration. Zura
Bio (whether on its own good faith determination or as the result of a request for withdrawal by persons or entities pursuant to separate
written contractual obligations) may withdraw a Registration Statement filed with the Commission in connection with a Piggyback Registration
at any time prior to the effectiveness of such Registration Statement, whether or not Athanor has elected to include Registrable Securities
in such registration. Zura Bio shall be responsible for the Registration Expenses incurred in connection with the Piggyback Registration
prior to its withdrawal under this <U>Section&nbsp;2.3.3</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>2.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Suspension
of Sales; Adverse Disclosure; Restrictions on Registration Rights</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>2.5.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Upon
receipt of written notice from Zura Bio that a Registration Statement or Prospectus contains a Misstatement, Athanor shall forthwith
discontinue disposition of Registrable Securities until it has received copies of a supplemented or amended Prospectus correcting the
Misstatement (it being understood that Zura Bio hereby covenants to prepare and file such supplement or amendment as soon as practicable
after the time of such notice), or until it is advised in writing by Zura Bio that the use of the Prospectus may be resumed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>2.5.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Subject
to <U>Section&nbsp;2.4.3</U>, if the filing, initial effectiveness or continued use of a Registration Statement in respect of any Registration
at any time would (i)&nbsp;require Zura Bio to make an Adverse Disclosure, (ii)&nbsp;require the inclusion in such Registration Statement
of financial statements that are unavailable to Zura Bio for reasons beyond Zura Bio&rsquo;s control or (iii)&nbsp;in the good faith
judgment of the board of directors, be seriously detrimental to Zura Bio and the board of directors concludes as a result that it is
essential to defer such filing, initial effectiveness or continued use at such time, Zura Bio may, upon giving prompt written notice
of such action to Athanor, delay the filing or initial effectiveness of, or suspend use of, such Registration Statement for the shortest
period of time, but in no event more than ninety (90) days in any 12-month period, determined in good faith by Zura Bio to be necessary
for such purpose. In the event Zura Bio exercises its rights under this <U>Section&nbsp;2.4.2</U>, Athanor agrees to suspend, immediately
upon its receipt of the notice referred to above, its use of the Prospectus relating to any Registration in connection with any sale
or offer to sell Registrable Securities until it receives written notice from Zura Bio that such sales or offers of Registrable Securities
may be resumed, and in each case maintain the confidentiality of such notice and its contents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>2.5.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>The
right to delay or suspend any filing, initial effectiveness or continued use of a Registration Statement pursuant to <U>Section&nbsp;2.4.2</U>
shall be exercised by Zura Bio, in the aggregate, not more than two (2)&nbsp;times or for more than sixty (60) consecutive calendar days,
or for more than one hundred and twenty (120) total calendar days, in each case during any 12-month period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;3</B></FONT><B><FONT STYLE="font-size: 10pt"><BR>
PAYMENTS AND TERMINATION</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Initial
Payment</B>. In partial consideration for executing this Agreement, Zura Bio shall pay to Athanor an initial fee in an amount equal to
$7,325,000 (the &ldquo;<B>Initial Fee</B>&rdquo;), which shall be due and payable within thirty (30) days after the Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Milestone
Payments</B>. In partial consideration for executing this Agreement, Zura Bio shall make a one-time milestone payment in the amount of
US$25,000,000 (the &ldquo;<B>Milestone Payment</B>&rdquo;) to Athanor after the occurrence of the earliest of any of the following events:
(i)&nbsp;Zura Bio or ZB17 undergoes a Change of Control, (ii)&nbsp;the consummation by Zura Bio or ZB17 of a sale of assets resulting
in net proceeds in excess of $500,000,000, or (iii)&nbsp;First Indication Regulatory Approval. Zura Bio shall promptly notify Athanor
in writing of, but in no event later than [***] after, the occurrence of any of the foregoing milestone events (which notice shall specify
the date of such occurrence) (a &ldquo;<B>Milestone Notice</B>&rdquo;); provided, however, that in no event shall a failure to deliver
a Milestone Notice relieve Zura Bio of its obligation to pay the Milestone Payment when due pursuant to this Section&nbsp;3.2. Zura Bio
shall pay the Milestone Payment within [***] after the occurrence of the earliest milestone event that triggered the Milestone Payment.
For clarity, the Milestone Payment shall only be payable once upon the first occurrence of the earliest triggering milestone event.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Net
Sales Payments</B>. In partial consideration for executing this Agreement, Zura Bio shall pay to Athanor an amount equal to two percent
(2%) of Net Sales for the Product (by Zura Bio and all Related Parties) to the extent such Net Sales are the subject of a royalty payment
under the Lilly Agreement (collectively, the &ldquo;<B>Net Sales Payments</B>&rdquo;). If applicable, the aggregate Net Sales in each
jurisdiction shall be converted to Dollars in accordance with Section&nbsp;3.6 for purposes of determining the aggregate Net Sales in
all jurisdictions. The aggregate Net Sales of the Product shall be for all products that fall within the definition of the Product taken
together (e.g., all formulations and dosages).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Payments</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.4.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;General</B>.
Zura Bio shall make all payments required by this Article&nbsp;3 by wire transfer of then immediately available funds into an account
designated by Athanor, and shall make such payments in Dollars. Each payment of the Initial Fee and the Milestone Payment shall be nonrefundable
and non-creditable against any other payments due hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.4.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Net
Sales Payments and Reports</B>. Zura Bio shall pay the Net Sales Payments on a Calendar Quarter basis, with respect to the aggregate
Net Sales for such Calendar Quarter. At the end of each Calendar Quarter, Zura Bio shall calculate the Net Sales Payments payable to
Athanor pursuant to Section&nbsp;3.3 for such Calendar Quarter, which amounts shall be converted to Dollars at such time in accordance
with Section&nbsp;3.6. Zura Bio shall pay to Athanor the Net Sales Payment due for the Product for Net Sales during a given Calendar
Quarter within [***] after the end of such Calendar Quarter. Each Net Sales Payment due to Athanor shall be accompanied by (a)&nbsp;a
statement of the amount of aggregate gross sales of the Product (i)&nbsp;in the Territory as a whole and (ii)&nbsp;on a country-by-country
basis, in each case, during the applicable Calendar Quarter (including such amounts expressed in local currency and as converted to Dollars),
and (b)&nbsp;an itemized calculation of Net Sales of the Product (A)&nbsp;in the Territory as a whole and (B)&nbsp;on a country-by-country
basis, in each case, during the applicable Calendar Quarter, showing for both (A)&nbsp;and (B)&nbsp;deductions provided for in the definition
of &ldquo;<B>Net Sales</B>&rdquo; during such Calendar Quarter. Without limiting the generality of the foregoing, Zura Bio shall require
its Related Parties (and any distributors) to account for their respective Net Sales and to provide such reports with respect thereto
as if such Net Sales were made by Zura Bio.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Taxes
and Withholding</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.5.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;VAT</B>.
The Parties agree to cooperate with one another and use commercially reasonable efforts to reduce or eliminate any value added tax, sales
tax, consumption tax, or other similar taxes (&ldquo;<B>VAT</B>&rdquo;) in respect of any payments made by Zura Bio to Athanor under
this Agreement. All payments made by Zura Bio to Athanor pursuant to this Agreement shall be made on a gross basis, without any deduction
of any applicable VAT (other than VAT resulting from an Athanor Action (as defined below). Notwithstanding the foregoing, if any VAT
results from an Athanor Action (as defined below), any payments made by Zura Bio to Athanor pursuant to this Agreement shall be made
after deduction of any such VAT and Athanor shall be solely responsible for such VAT resulting from an Athanor Action, such that Zura
Bio shall timely pay any VAT due in connection with such payments to the applicable Governmental Authority (following receipt by Zura
Bio of a valid VAT invoice) and shall remit the remaining amount of such payments (reduced by any applicable VAT) to Athanor. In the
event that any VAT borne by Athanor is later recovered by Zura Bio or an Affiliate, Zura Bio shall reimburse Athanor within [***] for
the deducted amount. In the event that any VAT is owed in any jurisdiction in respect of any such payment, Athanor will provide to Zura
Bio tax invoices showing the correct amount of VAT in respect of such payments hereunder and otherwise reasonably cooperate with Zura
Bio in connection with the payment or reporting of any VAT; provided, that Zura Bio shall be solely responsible for any VAT that does
not result from an Athanor Action. For purposes of this Section&nbsp;3.5.1, &ldquo;<B>Athanor Action</B>&rdquo; means (a)&nbsp;an assignment
of Athanor&rsquo;s (or its assignee&rsquo;s or successor&rsquo;s) rights or obligations under this Agreement (in whole or in part) (ii)&nbsp;the
exercise by Athanor (or its assignee or successor) of its rights or obligations under this Agreement (in whole or in part) through an
Affiliate or third party (or the direct exercise of such rights by an Affiliate of Athanor ); and (iii)&nbsp;a redomiciliation of Athanor
(or its assignee or successor).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.5.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Withholding
Tax Matters</B>. Zura Bio shall be entitled to deduct or withhold from any amounts payable to Athanor pursuant to this Agreement such
amounts as are required to be deducted or withheld therefrom under any Applicable Law. Any such amounts that are so deducted or withheld
and paid to the applicable Governmental Authority shall be treated for all purposes under this Agreement as having been paid to Athanor.
Upon Athanor&rsquo;s reasonable written request, Zura Bio shall deliver a tax payment certificate or other documentation (or a copy thereof),
to the extent issued by the applicable Government Authority, certifying payment of such amounts. Notwithstanding anything to the contrary
set forth in this Agreement, if Zura Bio or any of its Affiliates has made a payment to Athanor under this Agreement, and if a deduction
or withholding on account of taxes should have been, but was not, made from such payment (or should have been, but was not, made from
such payment at an increased rate, as applicable) under Applicable Law, upon receipt of a written request by Zura Bio and reasonable
evidence from Zura Bio that such deduction or withholding on account of Tax should have been made (or made at a higher rate), Athanor
shall promptly reimburse Zura Bio and its Affiliates for the amount of the tax that should have been (but was not) deducted or withheld
(and any penalties, interest or expenses payable or incurred in connection with any failure to pay or any delay in paying any of the
same).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.5.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tax
Cooperation</B>. Prior to the Effective Date and at such other times reasonably requested by Zura Bio, Athanor shall deliver to Zura
Bio a duly completed and validly executed Internal Revenue Service (&ldquo;<B>IRS</B>&rdquo;) Form&nbsp;W-9 or appropriate IRS Form&nbsp;W-8,
as applicable, and such other forms or documentation reasonably requested by Zura Bio to permit Zura Bio to determine its withholding,
information reporting, and other tax reporting or compliance obligations in connection with the transactions and payments contemplated
by this Agreement (collectively, the &ldquo;<B>Tax Forms</B>&rdquo;). In the event that any Tax Form&nbsp;previously provided by Athanor
to Zura Bio becomes expired, obsolete or inaccurate, Athanor shall promptly provide updated Tax Forms or advise of its inability to do
so pursuant to Applicable Laws. Without limiting the foregoing, Athanor shall use reasonable efforts to provide any such Tax Forms to
Zura Bio at least thirty (30) days prior to the due date for any payments for which Athanor desires that Zura Bio apply a reduced withholding
rate. Each Party shall provide the other with reasonable assistance to enable the recovery, as permitted by Applicable Laws, of withholding
taxes, VAT or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of the Party
bearing such withholding tax or VAT. The obligations of this Section&nbsp;3.5.3 shall apply <I>mutatis mutandis</I> to any transferee
or assignee of Athanor&rsquo;s rights under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Currency
Conversion</B>. All payments hereunder shall be made in Dollars. For the purpose of calculating any sums due under, or otherwise reimbursable
pursuant to, this Agreement (including the calculation of Net Sales expressed in currencies other than Dollars), any amount expressed
in a foreign currency shall be converted into Dollars in a manner consistent with such Party&rsquo;s normal practices used to prepare
its audited financial statements for external reporting purposes, in accordance with GAAP, consistently applied, or by using a reputable
source such as the Wall Street Journal or Reuters, at Athanor&rsquo;s discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Termination
of Letter Agreements</B>. The Letter Agreements are hereby terminated in their entirety and are of no further force or effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;4</B></FONT><B><FONT STYLE="font-size: 10pt"><BR>
REPRESENTATIONS AND WARRANTIES</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>4.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Mutual
Representations and Warranties</B>. Each Party hereby represents and warrants to the other Party as follows, as of the Effective Date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>4.1.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Corporate
Existence and Power</B>. It is a company or corporation duly incorporated or organized, validly existing, and in good standing under
the laws of the jurisdiction in which it is incorporated, and has full corporate power and authority and the legal right to own and operate
its property and assets and to carry on its business as it is now being conducted and as contemplated in this Agreement, including the
right to grant the licenses granted by it hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>4.1.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Authority
and Binding Agreement</B>. (a)&nbsp;It has the corporate power and authority and the legal right to enter into this Agreement and perform
its obligations hereunder, (b)&nbsp;it has taken all necessary corporate action on its part required to authorize the execution and delivery
of this Agreement and the performance of its obligations hereunder, and (c)&nbsp;this Agreement has been duly executed and delivered
on behalf of such Party, and constitutes a legal, valid and binding obligation of such Party that is enforceable against it in accordance
with its terms, except as enforcement may be affected by bankruptcy, insolvency or other similar laws and by general principles of equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>4.1.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
Conflicts</B>. The execution, delivery and performance of this Agreement by it does not (a)&nbsp;conflict with any agreement, instrument
or understanding, oral or written, to which it is a party and by which it may be bound or (b)&nbsp;violate any Applicable Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>4.1.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;All
Consents and Approvals Obtained</B>. All Governmental Authorities and other Persons required to be obtained or provided by such Party
as of the Effective Date in connection with the execution, delivery and performance of this Agreement have been obtained and provided,
except for those approvals, if any, not required at the time of execution of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>4.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Representations
and Warranties of Athanor</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>4.2.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Beneficial
Ownership</B>. Schedule A attached hereto reflects, as of the date of this Agreement, all securities of Zura Bio, ZB17, Z33 Bio, and
any other Zura Bio Affiliate Beneficially Owned by Athanor or any of its Affiliates or which Athanor or any of its Affiliates has the
right to acquire as of the date hereof. Athanor has good, marketable and valid title to and unrestricted power to vote and transfer the
Z33 Bio Shares to Zura Bio or its designee free and clear of any Encumbrances. Upon the closing of the Z33 Bio Share Transfer in accordance
with the terms of this Agreement, Zura Bio or its designee will obtain, good, marketable and valid title to the Z33 Bio Shares and unrestricted
power to vote and sell such shares free and clear of any Encumbrances</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>4.2.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Letter
Agreements</B>. Athanor has acquired all of Stone Peach&rsquo;s right, title and interest in and to the Letter Agreements and the Z33
Bio Shares pursuant to the Stone Peach Assignment. Neither Stone Peach nor any other third party has any rights under the Letter Agreements.
Upon the termination of the Letter Agreements as set forth herein, neither Athanor nor any other party shall have any rights under the
Letter Agreements and such agreements shall be null and void and of no further force or effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>4.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
Other Representations or Warranties</B>. EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT, NO REPRESENTATIONS OR WARRANTIES WHATSOEVER, WHETHER
EXPRESS OR IMPLIED,&nbsp;INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OR NON-MISAPPROPRIATION
OF THIRD-PARTY INTELLECTUAL PROPERTY RIGHTS, ARE MADE OR GIVEN BY OR ON BEHALF OF A PARTY. EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT,
ALL REPRESENTATIONS AND WARRANTIES, WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY EXCLUDED.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;5</B></FONT><B><FONT STYLE="font-size: 10pt"><BR>
CONFIDENTIALITY</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>5.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Confidential
Information</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>5.1.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>During
the Term, and for a period of [***] thereafter, Athanor will (a)&nbsp;maintain in confidence Confidential Information of Zura Bio to
the same extent Athanor maintains its own proprietary information of similar kind and value, (b)&nbsp;not disclose such Confidential
Information to any Third Party without the prior written consent of Zura Bio, except as otherwise expressly permitted below, and (c)&nbsp;not
use such Confidential Information for any purpose except those permitted by this Agreement. As used herein, &ldquo;<B>Confidential Information</B>&rdquo;
means all information and materials received by Athanor or its Affiliates from the Zura Bio or its Affiliates pursuant to this Agreement.
The foregoing obligations and the other obligations set forth in this Section&nbsp;5.1 shall not apply with respect to any portion of
such Confidential Information which:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt"><B>(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>is
publicly disclosed by Zura Bio, either before or after it becomes known to Athanor;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt"><B>(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>was
known to Athanor or any or its Affiliates, without any obligation to keep it confidential, prior to when it was received from Zura Bio;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt"><B>(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>is
subsequently disclosed to Athanor or any of its Affiliates by a Third Party that is lawfully in possession thereof without obligation
to keep it confidential;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt"><B>(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>has
been published by a Third Party or otherwise enters the public domain through no fault of Athanor or any of its Affiliates in breach
of this Agreement; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt"><B>(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>has
been independently developed or acquired by the receiving Party or any of its Affiliates without the aid, application or use of Zura
Bio&rsquo;s Confidential Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>5.1.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Athanor
shall have the right to disclose any Confidential Information provided by Zura Bio hereunder if such disclosure is necessary to comply
with the terms and conditions of this Agreement, or the requirements of any Applicable Law, but only to the extent of such necessity
or requirements, and no such disclosure shall cause any such information to cease to be Confidential Information hereunder, except to
the extent such disclosure results in a public disclosure of such information. Where reasonably possible, Athanor shall notify Zura Bio
of Athanor&rsquo;s intent to make such disclosure of Confidential Information pursuant to the preceding sentence sufficiently prior to
making such disclosure so as to allow Zura Bio adequate time to take whatever action Zura Bio may deem to be appropriate to protect the
confidentiality of the Confidential Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>5.1.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Except
as set forth above, Athanor agrees that it shall provide or permit access to Confidential Information of Zura Bio only to (a)&nbsp;Athanor&rsquo;s
attorneys, independent accountants and financial advisors for the sole purpose of enabling such attorneys, independent accountants and
financial advisors to provide advice to Athanor, and (b)&nbsp;Athanor&rsquo;s Affiliates, directors, officers, employees, consultants,
and advisors, who have a need to know such Confidential Information to assist Athanor with activities contemplated or required of it
by this Agreement; provided, that in each case the Person to whom Confidential Information is being disclosed is subject to obligations
of confidentiality and non-use with respect to such Confidential Information substantially similar to the obligations of confidentiality
and non-use of Athanor pursuant to this Section&nbsp;5.1; and provided, further, that Athanor shall remain responsible for any failure
by its attorneys, independent accountants and financial advisors, Affiliates, and its and its Affiliates&rsquo; respective directors,
officers, employees, consultants, and advisors, and any other parties to whom such Confidential Information is disclosed, to treat such
Confidential Information as required under this Section&nbsp;5.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>5.1.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Athanor
acknowledges that its breach of any of its obligations under this Section&nbsp;5.1 may cause Zura Bio irreparable harm, for which monetary
damages may be an inadequate remedy. Therefore, notwithstanding anything to the contrary in this Agreement in the event of any such breach,
Zura Bio shall be entitled, in addition to any other remedy available to it under this Agreement, at law or in equity, to seek injunctive
relief, including an accounting for profits, specific performance of the terms hereof and other equitable relief for such breach, without
the posting of bond or other security.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>5.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Publicity</B>.
Athanor agrees not to issue any press release or other public statement disclosing information relating to this Agreement or the transactions
contemplated hereby or the terms hereof without the prior written consent of Zura Bio.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>5.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Survival</B>.
The obligations and prohibitions contained in this Article&nbsp;5 as they apply to Confidential Information shall survive the expiration
or termination of this Agreement for a period of ten (10)&nbsp;years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;6</B></FONT><B><FONT STYLE="font-size: 10pt"><BR>
TERM AND TERMINATION</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>6.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Term</B>.
This Agreement shall become effective on the Effective Date and, unless earlier terminated pursuant to this Article&nbsp;6, shall remain
in effect on a country-by-country basis until the expiration of the obligation to pay Net Sales Payments in such country (the &ldquo;<B>Term</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>6.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Termination
for Material Breach</B>. Either Party may, first having tried and failed to resolve a Dispute in accordance with Section&nbsp;8.1, and
without prejudice to any other remedies available to it at law or in equity, terminate this Agreement in its entirety upon written notice
to the other Party in the event that the other Party (the &ldquo;<B>Breaching Party</B>&rdquo;) materially breached or defaulted in the
performance of any of its obligations (including a failure to perform). Unless the Breaching Party has cured or remedied any such breach
or default upon the conclusion of the dispute resolution procedure in Section&nbsp;8.1, such termination shall become effective upon
the Breaching Party&rsquo;s receipt of the written notice of termination to be given within [***] upon the conclusion of the dispute
resolution procedure in Section&nbsp;8.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;7</B></FONT><B><FONT STYLE="font-size: 10pt"><BR>
EFFECTS OF EXPIRATION OR TERMINATION</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>7.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Expiration
of Net Sales Payments</B>. Upon the expiration or termination (whether in its entirety or on a country-by-country basis) of the obligation
to pay Lilly a royalty on Net Sales for the Product (by Zura Bio and all Related Parties) in accordance with the Lilly Agreement, Zura
Bio shall have no further obligation to make any Net Sales Payments with respect to such corresponding Net Sales of the Product under
this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>7.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Termination</B>.
Upon termination (but not expiration) of this Agreement, in its entirety, or with respect to any given country(ies), all payment obligations
under Article&nbsp;3 shall cease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>7.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Accrued
Rights</B>. Expiration or termination of this Agreement for any reason will be without prejudice to any rights that will have accrued
to the benefit of a Party prior to the effective date of such expiration or termination. Such expiration or termination will not relieve
a Party from obligations that are expressly indicated to survive the expiration or termination of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>7.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Survival</B>.
Notwithstanding anything to the contrary contained herein, the following provisions shall survive any expiration or termination of this
Agreement: Article&nbsp;1 (Definitions), Section&nbsp;3.7 (Termination of Letter Agreements), Article&nbsp;5 (Confidentiality), Article&nbsp;7
(Effects of Expiration or Termination), Article&nbsp;8 (Dispute Resolution) and Article&nbsp;9 (Miscellaneous). Except as set forth in
this Article&nbsp;7 or otherwise expressly set forth herein, upon expiration or termination of this Agreement, all other rights and obligations
of the Parties shall cease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;8</B></FONT><B><FONT STYLE="font-size: 10pt"><BR>
DISPUTE RESOLUTION</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>8.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Disputes</B>.
The Parties recognize that, from time to time, disputes, controversies or claim may arise which stem from or are related to a Party&rsquo;s
respective rights or obligations under this Agreement or a Party&rsquo;s actual or alleged breach of this Agreement (a &ldquo;<B>Dispute</B>&rdquo;).
It is the desire of the Parties to establish procedures to facilitate the resolution of Disputes arising under this Agreement in an expedient
manner by mutual cooperation and without resort to litigation. To accomplish this objective, the Parties agree to follow the procedures
set forth in this Article&nbsp;8 if and when a Dispute arises under this Agreement. If the Parties are unable to resolve any Dispute
within thirty (30) days after such Dispute is submitted to it, either Party may, by written notice to the other Party, have such dispute
referred to Designated Officers of each Party for attempted resolution. If the Designated Officers cannot reach resolution of the Dispute
within thirty (30) days after such referral, the Dispute shall be referred to the Parties&rsquo; designated executive officers or their
delegates for attempted resolution. In the event the designated executive officers or their delegates are not able to resolve such Dispute
within such thirty (30)-day period after receipt of written notice, and a Party wishes to pursue the matter, then each Party may, in
its discretion, seek resolution of any and all Disputes that are not resolved under this Section&nbsp;8.1 in accordance with Section&nbsp;8.3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>8.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Choice
of Law</B>. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware without reference
to any rules&nbsp;of conflict of laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>8.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Arbitration</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>8.3.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Any
unresolved Dispute which was subject to Section&nbsp;8.1, shall be finally resolved by binding arbitration by the International Chamber
of Commerce (&ldquo;<B>ICC</B>&rdquo;) administered in accordance with the Rules&nbsp;of ICC in effect on the date of this Agreement
and applying the substantive law specified in Section&nbsp;8.2. Judgment on the arbitration award may be entered in any court having
jurisdiction thereof. The obligation to arbitrate under this Section&nbsp;8.3 shall extend to any claims by or against the Parties and
their respective Affiliates and any agents, principals, officers, directors, or employees of either of the Parties or their respective
Affiliates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>8.3.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>The
arbitration shall be conducted by three (3)&nbsp;arbitrators experienced in the business of pharmaceuticals. Within thirty (30) days
after initiation of arbitration, the Parties shall select the arbitrators. Zura Bio, on the one hand, shall select one (1)&nbsp;arbitrator
and Athanor, on the other hand, shall select one (1)&nbsp;arbitrator (or, if either Party fails to make a choice, the ICC shall select
one (1)&nbsp;arbitrator on behalf of such Party) and the two (2)&nbsp;arbitrators selected by the Parties will mutually select a third
arbitrator (or, if they fail to make a choice, the ICC shall select a third arbitrator). In making their determination, the arbitrators
shall not have the authority to modify any term or provision of this Agreement. A consensus decision of any two (2)&nbsp;of the arbitrators
shall be final, conclusive and binding on the Parties. The place of arbitration shall be New York, New York, and all proceedings and
communications shall be in English.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>8.3.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Prior
to the arbitrators being selected, either Party, without waiving any remedy under this Agreement, may seek a temporary restraining order
or preliminary injunction pursuant to Section&nbsp;8.3.5 prior to final resolution of the issue by the arbitrators or other resolution
of the controversy between the Parties. Once the arbitrators are in place, either Party may apply to the arbitrators for interim injunctive
relief until the arbitration award is rendered or the controversy is otherwise resolved, and either Party may apply to a court of competent
jurisdiction to enforce interim injunctive relief granted by the arbitrators. Any final award by the arbitrators may be entered by either
Party in any court having appropriate jurisdiction for a judicial recognition of the decision and applicable orders of enforcement. The
arbitrators may render early or summary disposition of some or all issues, after the Parties have had a reasonable opportunity to make
submissions on those issues. The arbitrators shall have no authority to award punitive or any other type of damages not measured by a
Party&rsquo;s compensatory damages. The Parties intend that each award rendered by an arbitrator hereunder shall be entitled to recognition
and enforcement under the United Nations Convention on the Recognition and Enforcement of Arbitral Awards (New York, 1958).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>8.3.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Except
to the extent necessary to confirm an award or as may be required by law, neither a Party nor an arbitrator may disclose the existence,
content, or results of an arbitration without the prior written consent of both Parties. In no event shall an arbitration be initiated
after the date when commencement of a legal or equitable proceeding based on the dispute, controversy or claim would be barred by the
applicable New York statute of limitations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>8.3.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Notwithstanding
anything in this Agreement to the contrary, a Party may seek a temporary restraining order or a preliminary injunction from any court
of competent jurisdiction in order to prevent immediate and irreparable injury, loss, or damage on a provisional basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;9</B></FONT><B><FONT STYLE="font-size: 10pt"><BR>
MISCELLANEOUS</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>9.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Entire
Agreement; Amendment</B>. This Agreement, together with the Schedules hereto, contains the entire understanding of the Parties with respect
to the subject matter hereof. Any other express or implied agreements and understandings, negotiations, writings and commitments, either
oral or written, in respect to the subject matter hereof are superseded by the terms of this Agreement. The Schedules to this Agreement
are incorporated herein by reference and shall be deemed a part of this Agreement. This Agreement may be amended, or any term hereof
modified, only by a written instrument duly executed by authorized representatives of each of the Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>9.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Force
Majeure</B>. No Party shall be liable for any failure to perform, or be considered in breach of, its obligations under this Agreement
(other than obligations to make payments of money) to the extent such performance has been delayed, interfered with or prevented by an
event of Force Majeure, and the obligations of such Party under this Agreement (other than obligations to make payments of money) whose
performance is affected by Force Majeure shall be suspended during, but not longer than, the continuance of the event of Force Majeure.
Any Party that experiences an event of Force Majeure shall provide prompt notice of such event to the other Party, including and an estimate
of the likely period of time during which its performance will be affected, and shall use reasonable efforts to remove the condition
constituting Force Majeure. In the event of a prolonged condition of Force Majeure that makes it unreasonable to continue to perform
other activities then being performed by the Parties and their Affiliates pursuant to this Agreement, the Parties shall consult directly
or through the appropriate committees and may appropriately scale back their respective activities in order to avoid waste or inappropriate
usage of resources under the circumstances, and neither Party shall be liable for any such reasonable scale back, or be considered in
breach of its obligations under this Agreement (other than obligations to make payments of money to the other Party) as a result of such
reasonable scale back.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>9.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notices</B>.
Any notice required or permitted to be given under this Agreement shall be in writing, shall specifically refer to this Agreement and
shall be deemed to have been sufficiently given for all purposes if: (i)&nbsp;mailed by first class certified or registered mail, postage
prepaid (which notice shall be effective five (5)&nbsp;Business Days after such mailing); (ii)&nbsp;mailed by express delivery service
(which notice shall be effective on the first Business Day after delivery to such service); (iii)&nbsp;sent by electronic mail or (iv)&nbsp;
personally delivered to the appropriate addresses (which notice shall be effective upon delivery to such addresses) set forth below or
to such other addresses or numbers for a Party as such Party may inform the other Party by giving five (5)&nbsp;Business Days&rsquo;
prior written notice:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">If to Athanor:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><FONT STYLE="font-size: 10pt">Maples Corporate Services Limited,
PO Box 309, Ugland House,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><FONT STYLE="font-size: 10pt">Grand Cayman, KY1-1104, Cayman
Islands<BR>
Attention: [***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><FONT STYLE="font-size: 10pt">Email: [***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">If to Zura Bio:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><FONT STYLE="font-size: 10pt">1489 W. Warm Springs Road, Suite&nbsp;110</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><FONT STYLE="font-size: 10pt">Henderson, NV 89014</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><FONT STYLE="font-size: 10pt">Attention: [***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><FONT STYLE="font-size: 10pt">With a copy to [***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>9.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Assignment</B>.
Athanor may not assign or transfer this Agreement or any rights or obligations hereunder without the prior written consent of Zura Bio.
Any assignment or transfer, or attempted assignment or transfer, by Athanor in violation of the terms of this Section&nbsp;9.4 shall
be null and void and of no legal effect. This Agreement shall be binding on, and inure to the benefit of, each Party, its successors
and permitted assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>9.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Severability</B>.
If any one or more of the provisions of this Agreement is held to be invalid or unenforceable by any court of competent jurisdiction
from which no appeal can be or is taken, such provision shall be considered severed from this Agreement and shall not serve to invalidate
any remaining provisions hereof. The Parties shall make a good-faith effort to replace any invalid or unenforceable provision with a
valid and enforceable one such that the objectives contemplated by the Parties when entering this Agreement may be realized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>9.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Cumulative
Remedies</B>. No remedy referred to in this Agreement is intended to be exclusive, but each shall be cumulative and in addition to any
other remedy referred to in this Agreement or otherwise available under Applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>9.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Ambiguities;
No Presumption</B>. Each of the Parties acknowledges and agrees that this Agreement has been diligently reviewed by and negotiated by
and between them, that in such negotiations each of them has been represented by competent counsel and that the final agreement contained
herein, including the language whereby it has been expressed, represents the joint efforts of the Parties hereto and their counsel. Accordingly,
in interpreting this Agreement or any provision hereof, no presumption shall apply against any Party hereto as being responsible for
the wording or drafting of this Agreement or any such provision, and ambiguities, if any, in this Agreement shall not be construed against
any Party, irrespective of which Party may be deemed to have authored the ambiguous provision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>9.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Headings</B>.
The headings for each Article&nbsp;and Section&nbsp;in this Agreement have been inserted for convenience of reference only and are not
intended to limit or expand on the meaning of the language contained in the particular Article&nbsp;or Section.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>9.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Interpretation</B>.
Except where the context expressly requires otherwise: (a)&nbsp;the use of any gender herein shall be deemed to encompass references
to either or both genders, and the use of the singular shall be deemed to include the plural (and vice versa); (b)&nbsp;the words &ldquo;<B>include,</B>&rdquo;
 &ldquo;<B>includes</B>&rdquo; and &ldquo;<B>including</B>&rdquo; shall be deemed to be followed by the phrase &ldquo;<B>without limitation</B>&rdquo;;
(c)&nbsp;the word &ldquo;<B>will</B>&rdquo; shall be construed to have the same meaning and effect as the word &ldquo;<B>shall</B>&rdquo;;
(d)&nbsp;any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such
agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions
on such amendments, supplements or modifications set forth herein); (e)&nbsp;any reference herein to any person shall be construed to
include the person&rsquo;s successors and assigns; (f)&nbsp;the words &ldquo;<B>herein,</B>&rdquo; &ldquo;<B>hereof</B>&rdquo; and &ldquo;<B>hereunder,</B>&rdquo;
and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof;
(g)&nbsp;all references herein to Articles, Sections, or Schedules shall be construed to refer to Articles, Sections or Schedules of
this Agreement, and references to this Agreement include all Schedules hereto; (h)&nbsp;the word &ldquo;<B>notice</B>&rdquo; means notice
in writing (whether or not specifically stated) and shall include notices, consents, approvals and other written communications contemplated
under this Agreement; (i)&nbsp;provisions that require that a Party, the Parties or any committee hereunder &ldquo;<B>agree,</B>&rdquo;
 &ldquo;<B>consent</B>&rdquo; or &ldquo;<B>approve</B>&rdquo; or the like shall require that such agreement, consent or approval be specific
and in writing, whether by written agreement, letter, email, approved minutes or otherwise (but excluding instant messaging); (j)&nbsp;references
to any specific law, rule&nbsp;or regulation, or article, section or other division thereof, shall be deemed to include the then-current
amendments thereto or any replacement or successor law, rule&nbsp;or regulation thereof; (k)&nbsp;the term &ldquo;<B>or</B>&rdquo; shall
be interpreted in the inclusive sense commonly associated with the term &ldquo;<B>and/or</B>&rdquo;; and (l)&nbsp;the term &ldquo;<B>to
the extent</B>&rdquo; shall be interpreted to mean the extent or degree to which a subject or thing extends, and shall not simply be
construed to mean the word &ldquo;<B>if.</B>&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>9.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
Waiver</B>. Any delay in enforcing a Party&rsquo;s rights under this Agreement or any waiver as to a particular default or other matter
shall not constitute a waiver of such Party&rsquo;s rights to the future enforcement of its rights under this Agreement, except with
respect to an express written and signed waiver relating to a particular matter for a particular period of time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>9.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
Third-Party Beneficiaries</B>. No person or entity other than Zura Bio, Athanor and their respective Affiliates, successors and permitted
assignees hereunder, shall be deemed an intended beneficiary hereunder or have any right to enforce any obligation of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>9.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Independent
Parties</B>. It is expressly agreed that the relationship between Zura Bio and Athanor shall not constitute a partnership, joint venture
or agency. Neither Zura Bio nor Athanor shall have the authority to make any statements, representations or commitments of any kind,
or to take any action, which shall be binding on the other Party, without the prior written consent of such other Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>9.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Counterparts;
Electronic Signatures</B>. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but
all of which together shall constitute one and the same instrument. This Agreement may be executed by delivery of electronically scanned
copies of original signatures delivered by electronic mail, and such signatures shall be deemed to bind each Party as if they were original
signatures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">[<I>No Further Text
on This Page</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">IN
WITNESS WHEREOF, the Parties have executed this Agreement by their duly authorized representatives as of the date first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>Zura Bio Limited</B> &nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>Athanor Capital</B> &nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 43%"><FONT STYLE="font-size: 10pt">/s/ Amit Munshi</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 43%"><FONT STYLE="font-size: 10pt">/s/ Parvinder Thiara</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Printed:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Amit Munshi</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Printed:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Parvinder Thiara</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Director</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Schedule A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Athanor Capital
and Affiliates Beneficial Ownership</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Athanor Capital - 2,924,000 class A
ordinary shares (as of December&nbsp;29, 2025)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 22; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>tm2531128d1_ex10-2.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT>Exhibit&nbsp;10.2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SETTLEMENT AND RELEASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Settlement and Release Agreement (the &ldquo;<B>Agreement</B>&rdquo;)
is made and entered by and between Stone Peach Properties LLC, a Georgia limited liability company (&ldquo;<B>Stone Peach</B>&rdquo;),
each of the individuals listed in Schedule B (each a &ldquo;<B>Stone Peach Principal</B>&rdquo; and, collectively, the &ldquo;<B>Stone
Peach Principals</B>&rdquo;), and Zura Bio Limited, a Cayman Islands exempted company (&ldquo;<B>Zura Bio</B>&rdquo;). Stone Peach, each
of the Stone Peach Principals, and Zura Bio are each referred to herein as a &ldquo;<B>Party</B>&rdquo; and collectively as the &ldquo;<B>Parties</B>.&rdquo;
Stone Peach and each Stone Peach Principal are each referred to herein as a &ldquo;<B>Stone Peach Party</B>&rdquo; and collectively as
the &ldquo;<B>Stone Peach Parties</B>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RECITALS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WHEREAS, Stone Peach contends that the agreements
listed in Schedule A (collectively, the &ldquo;<B>Stone Peach Agreements</B>&rdquo;) are legitimate and enforceable against Zura Bio or
its affiliates;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WHEREAS, Stone Peach and Athanor Capital (&ldquo;<B>Athanor
Capital</B>&rdquo;) have entered into an agreement dated September&nbsp;22, 2025 (the &ldquo;<B>Stone Peach &ndash; Athanor Agreement</B>&rdquo;)
whereby Stone Peach conveyed to Athanor Capital certain interests that it contends are based on the agreements listed in Schedule A;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WHEREAS, Zura Bio and Athanor Capital have negotiated
and intend to enter into an agreement that will supersede any potential rights of Stone Peach and resolve all potential disputes related
thereto between Zura Bio on the one hand, and Athanor Capital (and related Athanor entities) or any of the Stone Peach Parties, on the
other hand (the &ldquo;<B>Settlement Matters</B>&rdquo;), extinguishing all agreements between Zura Bio and its affiliates and Stone Peach;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WHEREAS, following good faith negotiations, as
part of the global resolution between Zura Bio, Athanor Capital, and Stone Peach, the Parties have entered into this Settlement and Release
Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WHEREAS, the Parties desire to fully and finally
resolve any and all claims, demands, liabilities, or rights Stone Peach or any of the Stone Peach Principals could assert against Zura
Bio or its affiliates, without admission of liability by any Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AGREEMENTS, RELEASES AND PROMISES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD><B>Effective Date</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Agreement shall be effective on the date
it has been executed by all Parties, which is hereinafter referred to as the &ldquo;<B>Effective Date</B>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD><B>Full and Final Release by Stone Peach</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a material inducement for, and in consideration
of, this Agreement, each Stone Peach Party, on behalf of itself, its predecessors, successors, affiliates, and assigns, and it and its
past, present, and future officers, directors, shareholders, members, partners, attorneys, agents, employees, managers, representatives,
assigns, and successors in interest, and all persons acting by, through, under, or in concert with it (together &ldquo;the <B>Releasing
Party</B>&rdquo;), hereby releases and discharges Zura Bio and its affiliates, together with its predecessors, successors, and assigns
and past, present, and future officers, directors, shareholders, members, partners, attorneys, agents, employees, managers, representatives,
assigns, and successors in interest, and all persons acting by, through, under, or in concert with it, and each of them, from all known
and unknown charges, including, but not limited to the agreements listed in Schedule A, along with any other complaints, claims, grievances,
liabilities, obligations, promises, agreements, controversies, damages, actions, causes of action, suits, rights, demands, costs, losses,
debts, penalties, fees, wages, medical costs, pain and suffering, mental anguish, emotional distress, expenses (including attorneys&rsquo;
fees and costs actually incurred), and punitive damages, of any nature whatsoever, known or unknown (each, a &ldquo;<B>Claim</B>&rdquo;)
which the Releasing Party has, or may have had, against Zura Bio or its affiliates, whether or not apparent or yet to be discovered, or
which may hereafter develop, for any acts or omissions related to or arising from the Settlement Matters (the &ldquo;<B>Released Claims</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Stone Peach Party, as the Releasing Party,
acknowledges it may hereafter discover facts different from, or in addition to, those it now believes to be true with respect to the Released
Claims. On its own behalf and on behalf of the Releasing Parties, each Stone Peach Party agrees the general release and waiver is effective
in all respects notwithstanding such different or additional facts or discovery, and this Agreement contemplates the extinguishment of
all such Released Claims. By executing this Agreement, each Stone Peach Party acknowledges the following: (a)&nbsp;it is represented by
legal counsel of its own choosing; (b)&nbsp;it has read and fully understands the provisions of California Civil Code &sect; 1542; and
(c)&nbsp;it has been specifically advised by legal counsel of the consequences of the above waiver and this Agreement generally.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Stone Peach Party, as the Releasing Party,
expressly waives the provisions of California Civil Code &sect;&nbsp;1542, which provides: &ldquo;A general release does not extend to
claims that the creditor or releasing party does not know or suspect to exist in their favor at the time of executing the release and
that, if known by them, would have materially affected their settlement with the debtor or released party.&rdquo; The Releasing Party
understands and acknowledges the significance and consequences of this specific waiver of Section&nbsp;1542 and intends this release to
be a full and unconditional release of all claims, whether known or unknown.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Agreement resolves any claim for relief that
is or could have been alleged, no matter how characterized, including, without limitation, compensatory damages, damages for breach of
contract, bad faith damages, reliance damages, liquidated damages, damages for humiliation and embarrassment, damage for interference
with contractual or business relations, punitive damages, costs, and attorneys&rsquo; fees related to or arising from any action, agreement,
matter, or claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">3.</TD><TD><B>Termination of Other Agreements</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of this Agreement, Zura Bio and Stone
Peach, agree that, as between Zura Bio and its affiliates and any of the Stone Peach Parties, each of the Stone Peach Agreements in Schedule
A are rendered null and void, and unenforceable in part or in whole by any Stone Peach Party. Moreover, the Parties agree that nothing
in this Agreement supports the conclusion that the Stone Peach Agreements identified in Schedule A were ever legitimate and enforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">4.</TD><TD><B>Representations and Warranties by the Stone Peach Parties</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">a.</TD><TD STYLE="text-align: justify">Each Stone Peach Party represents and warrants that there exist no other contracts, agreements, promises,
or other obligations of any kind, between such Stone Peach Party and Zura Bio or its affiliates, other than those identified in this Agreement
and those listed in Schedule A.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">b.</TD><TD STYLE="text-align: justify">Each Stone Peach Party represents and warrants that the individuals and entities listed in Schedule B
have been the only officers, directors, managers, members, 5% or greater shareholders (or members or security holders of any kind), administrators,
or related parties (as that term is defined in 17 CFR &sect; 229.404) of Stone Peach since December&nbsp;8, 2022, Schedule B properly
lists all roles and titles each such person has or held with Stone Peach since December&nbsp;8, 2022, and that no such individuals or
entities have been immediate family members of any Zura Bio director, officer, or manager since December&nbsp;8, 2022.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">c.</TD><TD STYLE="text-align: justify">Each Stone Peach Party represents and warrants that it does not hold any pre-funded warrants, private
warrants, options, shares, units or other equity holding of Zura Bio or its affiliates other than 2,701,543 class A ordinary shares of
Zura Bio Limited, par value US$0.0001 per share (Nasdaq: ZURA) as of the date of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">d.</TD><TD STYLE="text-align: justify">Each Stone Peach Party represents and warrants that it has received substantial consideration for entering
into this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">5.</TD><TD><B>Entire Agreement</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Agreement constitutes the entire understanding
and agreement between the Parties concerning the subject matter hereof and supersedes all prior and contemporaneous agreements, negotiations,
and communications, whether written or oral, relating to such subject matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">6.</TD><TD><B>Governing Law and Venue</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Agreement shall be governed by and construed
in accordance with the laws of Delaware without regard to its conflict of law principles. The Parties also agree that the venue of any
action to enforce the provisions of this Agreement, or any document executed in connection with this Agreement, shall be in Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">7.</TD><TD><B>No Right of Rescission</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In entering into this Agreement, each Party assumes
the risk of any mistake of fact or law. If any Party should later discover that any fact they relied upon in entering into this Agreement
is not true, or that their understanding of the facts or law was incorrect, such Party shall not be entitled to seek rescission of this
Agreement or revival of any Released Claims by reason of such discovery. This Agreement is intended to be, and is, final and binding upon
the Parties regardless of any mistake of fact or law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">8.</TD><TD><B>Fees and Costs Previously Incurred</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Party shall be responsible for its own attorneys&rsquo;
fees and costs previously incurred in connection with the Settlement Matters, this Agreement, or the Released Claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">9.</TD><TD><B>Authority to Execute</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Party acknowledges that they have carefully
read and fully understand all of the provisions of this Agreement; that they agree to all of the provisions of this Agreement; that each
Party is voluntarily entering into this Agreement; and that each Party has the capacity to enter into this Agreement. The Parties also
each represent and declare that in executing this Agreement they have relied upon their own judgment, belief, and knowledge.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Party and the person signing on behalf of
each Party represents that the person signing this Agreement has the authority to execute this document and thereby bind the Party hereto
on whose behalf the person is signing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">10.</TD><TD><B>Construction of the Agreement</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each of the Parties to this Agreement represents
that they have had a full opportunity to participate in the negotiation and drafting of this Agreement and that each Party has entered
into this Agreement for reasons of its own and not based upon the representations of any other Party hereto except as expressly set forth
in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">11.</TD><TD><B>Invalidity or Unenforceability</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that any provision of this Agreement
is found to be invalid or unenforceable because it violates any statute, rule, regulation or common law, all other provisions of this
Agreement shall remain in full force and effect. Notwithstanding the foregoing, the Parties acknowledge and agree that the Release set
forth above, is necessary to this Agreement, without which the Parties would not have reached this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">12.</TD><TD><B>No Reliance on Parol Evidence or Other Representations</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consideration provided in this Agreement contains
the entire consideration to which the Parties will be entitled to exchange for the agreements set forth herein. Except as expressly stated
in this Agreement, no Party (or any director, officer, agent, employee, representative or attorney of any Party) has made any statement,
representation or warranty to any other Party regarding any fact relied upon in entering into this Agreement, and no Party is relying
upon any statement, representation, warranty or promise of any other Party (or any director, officer, agent, employee, representative
or attorney of any Party) in executing this Agreement or in making this settlement, except as expressly stated in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">13.</TD><TD><B>Amendment or Modifications</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Agreement may not be altered, amended, modified,
or otherwise changed, except by a written agreement executed by a duly authorized representative of each Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">14.</TD><TD><B>Counterparts</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Agreement may be executed in counterparts,
each of which shall be deemed an original and all of which together shall constitute one and the same instrument. Execution and delivery
by electronic means (e.g., PDF or DocuSign) shall be valid and binding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Signature pages&nbsp;to follow.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: December&nbsp;22, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-bottom: Black 1pt solid; width: 50%; text-align: left">/s/ Baljit Lehal</TD><TD STYLE="text-align: justify; width: 50%">&nbsp;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Baljit Lehal</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stone Peach Properties, LLC &ndash; Director</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: December&nbsp;22, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-bottom: Black 1pt solid; width: 50%; text-align: left">/s/ Kanwarjeet Tucker</TD><TD STYLE="text-align: justify; width: 50%">&nbsp;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kanwarjeet Tucker</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On behalf of Stone Peach Properties, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: December&nbsp;22, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-bottom: Black 1pt solid; width: 50%; text-align: left">/s/ Kanwarjeet Tucker</TD><TD STYLE="text-align: justify; width: 50%">&nbsp;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kanwarjeet Tucker</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stone Peach Properties, LLC &ndash; Director</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: December&nbsp;29, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-bottom: Black 1pt solid; width: 50%; text-align: left">/s/ Kim Davis</TD><TD STYLE="text-align: justify; width: 50%">&nbsp;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kim Davis,&nbsp;Interim Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Zura Bio Limited</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Schedule A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">December&nbsp;8, 2022 Z33 Founder Issuance Agreement between Z33 Bio
Inc. and Stone Peach Properties LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">December&nbsp;8, 2022 Series&nbsp;Seed Preferred Stock Investment Agreement
between Zura Bio Limited and Stone Peach Properties LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">December&nbsp;8, 2022 Side Letter Agreement by and between Stone Peach
Properties LLC and Zura Bio Limited</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">December&nbsp;2022 Confidentiality and Non-Circumvention Agreement
by and between Stone Peach Properties LLC and Zura Bio Limited</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April&nbsp;24, 2023 Letter Agreement by and between Stone Peach Properties
LLC, Zura Bio Limited, and ZB17 LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">November&nbsp;21, 2023 Amendment to Letter Agreements by and between
Stone Peach Properties LLC, ZB17 LLC, and Zura Bio Limited</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Schedule B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Baljit Lehal &ndash; Director (since at least December&nbsp;8, 2022)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kanwarjeet Tucker &ndash; Director (since at least December&nbsp;8,
2022)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>tm2531128d1_ex10-3.htm
<DESCRIPTION>EXHIBIT 10.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><FONT>Exhibit&nbsp;10.3</FONT></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SETTLEMENT AND RELEASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Settlement and Release Agreement (the &ldquo;<B>Agreement</B>&rdquo;)
is made and entered by and between BAFFX17 LLC, a Delaware limited liability company and BAFFX17 Ltd, a limited company incorporated under
the laws of England and Wales (&ldquo;<B>BAFFX17</B>&rdquo;), each of the individuals listed in Schedule B (each a &ldquo;<B>BAFFX17 Principal</B>&rdquo;
and, collectively, the &ldquo;<B>BAFFX17 Principals</B>&rdquo;) and Zura Bio Limited (&ldquo;<B>Zura Bio&rdquo;</B>), an exempted company
incorporated under the laws of the Cayman Islands with its registered office at Maples Corporate Services Limited, P.O.&nbsp;Box 309,
Ugland House, South Church Street, George Town, Grand Cayman KY1-1104, Cayman Islands. BAFFX17 and Zura Bio are each referred to herein
as a &ldquo;<B>Party</B>&rdquo; and collectively as the &ldquo;<B>Parties</B>.&rdquo; BAFFX17 and each BAFFX17 Principal are each referred
to herein as a &ldquo;<B>BAFFX17 Party</B>&rdquo; and collectively as the &ldquo;<B>BAFFX17 Parties</B>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RECITALS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WHEREAS, BAFFX17 contends that the agreements
listed in Schedule A (collectively, the <B>&ldquo;BAFFX17 Agreements&rdquo;</B>) are legitimate and enforceable against Zura Bio or its
affiliates;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WHEREAS, the Parties desire to fully and finally
resolve any and all claims, demands, liabilities, or rights BAFFX17 or any of the BAFFX17 Principals could assert against Zura Bio or
its affiliates, without admission of liability by either Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AGREEMENTS, RELEASES AND PROMISES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>1.</B></TD><TD><B>Effective Date</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Agreement shall be effective on the date it has been signed by
Zura Bio, which is hereinafter referred to as the &ldquo;<B>Effective Date</B>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>2.</B></TD><TD><B>Full and Final Release by BAFFX17</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a material inducement for, and in consideration
of, this Agreement, each BAFFX17 Party, on behalf of itself, its predecessors, successors, affiliates, and assigns, and it and its past,
present, and future officers, directors, shareholders, members, partners, attorneys, agents, employees, managers, representatives, assigns,
and successors in interest, and all persons acting by, through, under, or in concert with it (together &ldquo;the <B>Releasing Party</B>&rdquo;),
hereby releases and discharges Zura Bio and its affiliates, together with its predecessors, successors, and assigns and past, present,
and future officers, directors, shareholders, members, partners, attorneys, agents, employees, managers, representatives, assigns, and
successors in interest, and all persons acting by, through, under, or in concert with it, and each of them, from all known and unknown
charges, including, but not limited to the BAFFX17 Agreements, along with any other complaints, claims, grievances, liabilities, obligations,
promises, agreements, controversies, damages, actions, causes of action, suits, rights, demands, costs, losses, debts, penalties, fees,
wages, medical costs, pain and suffering, mental anguish, emotional distress, expenses (including attorneys&rsquo; fees and costs actually
incurred), and punitive damages, of any nature whatsoever, known or unknown (each, a &ldquo;<B>Claim</B>&rdquo;) which the Releasing Party
has, or may have had, against Zura Bio or its affiliates, whether or not apparent or yet to be discovered, or which may hereafter develop,
for any acts or omissions related to or arising from the Settlement Matters (the &ldquo;<B>Released Claims</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each BAFFX17 Party, as the Releasing Party, acknowledges
it may hereafter discover facts different from, or in addition to, those it now believes to be true with respect to the Released Claims.
On its own behalf and on behalf of the Releasing Parties, each BAFFX17 Party agrees the general release and waiver is effective in all
respects notwithstanding such different or additional facts or discovery, and this Agreement contemplates the extinguishment of all such
Released Claims. By executing this Agreement, each BAFFX17 Party acknowledges the following: (a)&nbsp;it is represented by legal counsel
of its own choosing; (b)&nbsp;it has read and fully understands the provisions of California Civil Code &sect; 1542; and (c)&nbsp;it has
been specifically advised by legal counsel of the consequences of the above waiver and this Agreement generally.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each BAFFX17 Party, as the Releasing Party, expressly
waives the provisions of California Civil Code &sect;&nbsp;1542, which provides: &ldquo;A general release does not extend to claims that
the creditor or releasing party does not know or suspect to exist in their favor at the time of executing the release and that, if known
by them, would have materially affected their settlement with the debtor or released party.&rdquo; The Releasing Party understands and
acknowledges the significance and consequences of this specific waiver of Section&nbsp;1542 and intends this release to be a full and
unconditional release of all claims, whether known or unknown.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Agreement resolves any claim for relief that
is, or could have been alleged, no matter how characterized, including, without limitation, compensatory damages, damages for breach of
contract, bad faith damages, reliance damages, liquidated damages, damages for humiliation and embarrassment, damage for interference
with contractual or business relations, punitive damages, costs, and attorneys&rsquo; fees related to or arising from any action, agreement,
matter, or claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>3.</B></TD><TD><B>Termination of Other Agreements</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of this Agreement, Zura Bio and BAFFX17
agree that the BAFFX17 Agreements are rendered null and void, and unenforceable in part or in whole by any BAFFX17 Party. Moreover, the
Parties agree that nothing in this Agreement supports the conclusion that the BAFFX17 Agreements were ever legitimate and enforceable.
However, to the extent the BAFFX17 Agreements could be deemed legitimate and enforceable, they are hereby terminated in their entirety
and are of no further force or effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>4.</B></TD><TD><B>Representations and Warranties by BAFFX17</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">a.</TD><TD STYLE="text-align: justify">Each BAFFX17 Party represents and warrants that there exist no other contracts, agreements, promises,
or other obligations of any kind, between such BAFFX17 Party and Zura Bio or its affiliates other than those identified in this Agreement
and those listed in Schedule A.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">b.</TD><TD STYLE="text-align: justify">Each BAFFX17 Party represents and warrants that the individuals and entities listed in Schedule B have
been the only officers, directors, managers, members, 5% or greater shareholders (or members or security holders of any kind), administrators,
or related parties (as that term is defined in 17 CFR &sect; 229.404) of BAFFX17 since December&nbsp;8, 2022, and that no such individuals
or entities have been immediate family members of any Zura Bio director, officer, or manager since December&nbsp;8, 2022.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">c.</TD><TD STYLE="text-align: justify">Each BAFFX17 Party represents and warrants that it does not hold any pre-funded warrants, private warrants,
options, shares, units or other equity holding of Zura Bio or its affiliates as of the date of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">d.</TD><TD STYLE="text-align: justify">Each BAFFX17 Party represents and warrants that it has received substantial consideration for entering
into this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>5.</B></TD><TD><B>No Litigation by Zura Bio</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In exchange for the consideration in this Agreement,
Zura Bio agrees that it will not file litigation against BAFFX17 or any BAFFX17 Party contesting the legitimacy of the BAFFX17 Agreements,
or litigation otherwise seeking to declare those agreements (or any other obligation asserted by BAFFX17) null and void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>6.</B></TD><TD><B>Entire Agreement</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Agreement constitutes the entire understanding
and agreement between the Parties concerning the subject matter hereof and supersedes all prior and contemporaneous agreements, negotiations,
and communications, whether written or oral, relating to such subject matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>7.</B></TD><TD><B>Governing Law and Venue</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Agreement shall be governed by and construed
in accordance with the laws of Delaware without regard to its conflict of law principles. The Parties also agree that the venue of any
action to enforce the provisions of this Agreement, or any document executed in connection with this Agreement, shall be in Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>8.</B></TD><TD><B>No Right of Rescission</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In entering into this Agreement, each Party assumes
the risk of any mistake of fact or law. If any Party should later discover that any fact they relied upon in entering into this Agreement
is not true, or that their understanding of the facts or law was incorrect, such Party shall not be entitled to seek rescission of this
Agreement or revival of any Released Claims by reason of such discovery. This Agreement is intended to be, and is, final and binding upon
the Parties regardless of any mistake of fact or law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>9.</B></TD><TD><B>Fees and Costs Previously Incurred</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each Party shall be responsible for its own attorneys&rsquo; fees and
costs previously incurred in connection with this Agreement or the Released Claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>10.</B></TD><TD><B>Authority to Execute</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Party acknowledges that they have carefully
read and fully understand all of the provisions of this Agreement; that they agree to all of the provisions of this Agreement; that each
Party is voluntarily entering into this Agreement; and that each Party has the capacity to enter into this Agreement. The Parties also
each represent and declare that in executing this Agreement they have relied upon their own judgment, belief, and knowledge.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Party and the person signing on behalf of
each Party represents that the person signing this Agreement has the authority to execute this document and thereby bind the Party hereto
on whose behalf the person is signing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>11.</B></TD><TD><B>Construction of the Agreement</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each of the Parties to this Agreement represents
that they have had a full opportunity to participate in the negotiation and drafting of this Agreement and that each Party has entered
into this Agreement for reasons of its own and not based upon the representations of any other Party hereto except as expressly set forth
in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>12.</B></TD><TD><B>Invalidity or Unenforceability</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that any provision of this Agreement
is found to be invalid or unenforceable because it violates any statute, rule, regulation or common law, all other provisions of this
Agreement shall remain in full force and effect. Notwithstanding the foregoing, the Parties acknowledge and agree that the Release set
forth above, is necessary to this Agreement, without which the Parties would not have reached this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>13.</B></TD><TD><B>No Reliance on Parol Evidence or Other Representations</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consideration provided in this Agreement contains
the entire consideration to which the Parties will be entitled to exchange for the agreements set forth herein. Except as expressly stated
in this Agreement, no Party (or any director, officer, agent, employee, representative or attorney of any Party) has made any statement,
representation or warranty to any other Party regarding any fact relied upon in entering into this Agreement, and no Party is relying
upon any statement, representation, warranty or promise of any other Party (or any director, officer, agent, employee, representative
or attorney of any Party) in executing this Agreement or in making this settlement, except as expressly stated in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>14.</B></TD><TD><B>Amendment or Modifications</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Agreement may not be altered, amended, modified,
or otherwise changed, except by a written agreement executed by a duly authorized representative of each Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>15.</B></TD><TD><B>Counterparts</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Agreement may be executed in counterparts,
each of which shall be deemed an original and all of which together shall constitute one and the same instrument. Execution and delivery
by electronic means (e.g., PDF or DocuSign) shall be valid and binding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Signature pages&nbsp;to follow.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: December&nbsp;22, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-bottom: Black 1pt solid; width: 50%; text-align: left">/s/ Lahmber Singh</TD><TD STYLE="text-align: justify; width: 50%">&nbsp;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name: Lahmber Singh</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On behalf of BAFFX17</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: December&nbsp;17, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-bottom: Black 1pt solid; width: 50%; text-align: left">/s/ Lahmber Singh</TD><TD STYLE="text-align: justify; width: 50%">&nbsp;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lahmber Singh</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BAFFX17&ndash; Director</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: December&nbsp;18, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-bottom: Black 1pt solid; width: 50%; text-align: left">/s/ Asim Mohammed</TD><TD STYLE="text-align: justify; width: 50%">&nbsp;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Asim Mohammed</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BAFFX17&ndash; Former Director</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: December&nbsp;29, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 50%">/s/ Kim Davis</TD>
    <TD STYLE="width: 50%">&nbsp;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kim Davis,&nbsp;Interim Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Zura Bio Limited</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Schedule A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April&nbsp;25, 2023 Side Letter between BAFFX17 Ltd and Zura Bio Limited</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">December&nbsp;18, 2023 Amendment # 1 to April&nbsp;25, 2023 Side Letter</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Schedule B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Asim Mohammed &ndash; Director (September&nbsp;2, 2022 &ndash; July&nbsp;29,
2025)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lahmber Singh &ndash; Director (July&nbsp;29, 2025 to present)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>zura-20251229.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWa6JibOdzZR+WYkxtmB7bRla3yolYYb7HygTrX+G4e4O -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:zura="http://zurabio.com/20251229" elementFormDefault="qualified" targetNamespace="http://zurabio.com/20251229">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://zurabio.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="zura-20251229_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="zura-20251229_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>zura-20251229_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>zura-20251229_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="zura-20251229.xsd#Cover" roleURI="http://zurabio.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://zurabio.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Dec. 29, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 29,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Zura Bio Limited<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001855644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1725736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">E9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1489 W. Warm Springs Rd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">#110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Henderson<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">89014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">702<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">825-9872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A Ordinary Shares, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ZURA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="tm2531128d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zurabio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2531128d1_8k.htm">tm2531128d1_8k.htm</File>
    <File>zura-20251229.xsd</File>
    <File>zura-20251229_lab.xml</File>
    <File>zura-20251229_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2531128d1_8k.htm": {
   "nsprefix": "zura",
   "nsuri": "http://zurabio.com/20251229",
   "dts": {
    "inline": {
     "local": [
      "tm2531128d1_8k.htm"
     ]
    },
    "schema": {
     "local": [
      "zura-20251229.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "zura-20251229_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "zura-20251229_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 24
   },
   "report": {
    "R1": {
     "role": "http://zurabio.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-29",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2531128d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-29",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2531128d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://zurabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001104659-26-000209-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-26-000209-xbrl.zip
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MNA3:3^92!/4__RAW(K]F,&TEA85+NRX?D ]VGPX&RLHYIGWA3K1!E/H)\SS
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MR:/PXZ-)!&<QC+:DR7/)?-Y )LZ7^^[.JMBUKCS2I0UIYE7Y:GEOJ_C\7GM
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M^+ "PMRHUR%P2IMETMPIFD63%=,5%W?@N$K3WVYGQQN;4.UGV&@^CV(8J^!
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MTRA'/9(EJ^O-,7(KL,4V KS,[?W09C-(F YI@@XJ0AB3=;QT"*'WWY%$XZG
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M(QSF [SEN']RTC\:O^N=*+RPC]\.![^\&8\"U1OVU=O><1^'^V7P:_]4'7[
MO\_@C_Z;WLEK))<I^O"9DPG2\.2D-IU^Z-=,(A R&.%$X>.!1+H:GWW2>T_T
MX$7O!S@32#)\Z,.5E@J@#&:Z?_Q =N%]AD.>?!/AD(-M..3!9)@\^_P,DZ.S
MT]>#8Q S@QY*U&U*2=-YO"%<E2.GQ56W,[")^EN/1_,B;*X/ZS'AL'%V!>;5
M<4R),MR5[6[',!)4Q"H0^1[$@_'BFT9F[!B=2QVCN][*66[7!4(I^013#8):
M5\?JI^AQ"].\FVM0P&3.,<7$&U%'DC[&J:F#*2,G?(@NTAEWB)3\SU:&U-G@
M8S)E.&"F86@H"D@% DY;[T)*<JUGQT;(;(:PY.4F:S<M'U%A*M%"H+3;*9NH
M]*;1%"1(PK(\DGW$7N)_#;9'4G2UV63K4-H>YI2E=#L,)H'FC[L&^ H+1#.)
MT5EOVN/Z[JEJW2@6$9 Y6O&:.->T5[\+0I-MS>"&8K6ARZ:?^TN]_MFK&8"-
M)\8=<@Q7#5215&G:,4>9>$\JB%L7BEQOWU(.VQW/&10@&Q)PV+9T6<*B3Y.U
MV?65 COQ%;!6ITPO%FK!S&52'U,4.K:T_0_7W[^"-9QL; VO0UC$ZA(8SW55
M3OA 87X/DX]1M,1U=9ML!K;,BQJ9Q%R0;N265X6_7?CZPD\WNGF+<E*0<;;R
M-G #(]1"& BZXQW=.M<E":\Q&91+_;.B@+,X9I<CAC(,_UC>H>+))N;9\D.=
M'V8;XX=+% 0,\X(BO;@4)#9OD;U:++(T"RGGPE- S;(%M]IE<"?TSX:(ON4@
M,K4R%-R'#@!$VJD%?%XJC-ANF:'"#-$?P Q(%/;?%1D178$JO>24#A-#$80=
MENJH(AIF:5YJ5\L/8\PBYTP@#;LBO7M-";Z)R+0I?UN[ML&NW4AL#9FC@F)#
M01Y:?].[61N N/RM"KN;$60L$UM#JC&]93 $E,'T?I.-2B"QBR6V1:_$BR5S
M<Q;[-<M.^%B*4"671YH\S!N2TAC.B'J3^=A2IG,XT4.)OH1H: =D<S/-:F^A
MVS>4A5,^'_MV\11AD22+JG4"G3Q8;96*G>\VJW*>K'%4J?)4BVS[LWXGAY8]
M]1Z?XF)(X)D>$_R$CQ60<G] VX.NH9H[IK[J^%ZV;XM/0#NW5$*G2Y0VW',
MSZ&4RDWGF+7!DDKKG=@B_J.I<W>7(:/2U Q-[.S: 1*883^QE61VX=.0U&O0
M;B)"*N-\-',Y9CK.@*]DL5P$#X9)6 E8?;?3T'T>W^2!"[7[C)X\_2:B)T^V
MT9.O]<S=2(@=S]P^"7A*E[6>M7"273ERF/(F!!<E7E4P3C %ET%^0H(S1>ET
M)]^Q/OR,([HBU($F8*8\C=8$(&"T18V6%^K<#@M)0!@V66X1[1 >QX6$(* 5
MVT_F3N-W.PT/<)%J9@3'9&U;\0=/FE_+<WHP &V6$YH+G#&$6("EA-DZPM\)
M,CXA4J1YC:8 6R=ED@<#R@(;U^ANN<7MC.<28<]XJ--T^EQQBJ-7S6AUCQGK
MVPW82#5H9;>C#2/#4!HW.VNR13MQ<2$EEM9E %_I'IA8TVD=P:0'5$\^W40-
M5:"JU_?F>4&/!<XSYV8:0'ZI>/:1:BI/M;W;Q+YH17ZM>JI?^LGB.NE(IM%7
M@QCGO!&=6G 1:6D(J^/W[IO 8TZ-%%E'C!1>=AOM6$[&A;F%E97/R1HJTN9Y
MQ9PJ2MQR\[K%A646JB(A(%I!UFV]*W1*"AP(H.KZ/!!-Z7Z/HHU4CGCF'^A/
M(,B2:'9A3YU"G#A.8^]J^=X-"TG:-%M&YOR)<\*W(8OL,L0HJH4$6V0IA2F[
MG5FXP"ZMICH.'1=&DT>+;+:FTJJ<]",JY;@3D&^]3ESWY&*X.!>CG]\\J#7/
M=/"I&6)GQJ:ICG'Q?F(BG9:8\"N<UBTXO]A@_5H0U;EHCW95$44?X:O?RI2V
M.[;.2.)H[M:VV_::NB\9"+9YC-N=^ZF#45@KIM&FM3AQ;>4//9O(Y2?9[A8R
M&]K9PX8I'/ :\'^2<6F8E"AR[OZW5'IX]T21C7ARSLG^ARF7-CP5+1+#LLB!
MB*'-D5B,JN,JDVO"+)RX$6PO0Q'SN,H^3*1 ?-5KE$4)=$$?R5BVZHT GN@+
M75;\K(R!+7<U<-=&;)91F5_%5Z:=<!5'4/2IRW@B3CI<;J[+,P+7[2?\3&#$
MUI(J<)/QPD*W( )T!?HRSD.#AE[+?/>XL9J?@ZRT\WA?K(1UA#!V#Y&-[CUQ
M\/GG)PZ.^\.WE)2,?PQ.*>]XFSW8M&V?;R9M#=/4S)9M;(:%.1M29(';2XI)
MZGC, 6@N"9X8L&% ,;"[#HO1:LE&[EY_'GBF%,$K\@-52X]6;F*F4*5)*AM>
MJR]^J@+"TC=T3(Y35EWTL#L5^&"9'(,<_!#%P)>RY49T%0^5$ 7T6TF!4X>D
M94IU2>P@GH$A )9"G!<KW<)DE<=2]HV&.'MB0*=!M S@JN.X6):K2L-J5>]7
M_2,V@R)WD]8\0#'Z#53K:=2@SU.9?$6C;];=]>YHL#;0@#+8B=3^0JLX&'/!
M@LD&Q+>X!FI=O:+"W3R3)GKK 97KC$,X>5FM9Y?3+*+POL%X['8JAD.+!>A
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M#^I6 9=+YS$H6J&6FLC81L 86 I@MP1QXG13)!T'X:9(+A\24IA&QN.GHC,
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M#P4:W83OI!K A==HZ+ND<W^-NS'Z)%4I'#0B86QWB7F@B/!JWR4=BKC3PSU
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M<@/:*=RX;<56L8OSR+;'*P)UC,PF ,EC,Z%.KR(SCY@L640?A-T D(;(#[,
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MBPT%)0FPICVA'NODRGF!$_!?Y16Q/Q8&(2L##W;$R; XO@0\2@GB4%9*KTB
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MS785   !B0  %@   '1M,C4S,3$R.&0Q7V5X,3 M,RYH=&WM7>EOVSC:_V[
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MQY:""0 &&;!A[&$&]3J3&I<((+'RC7!9<4PA#YRH18V$,[<YM,#QP#R/:_1
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M](D?E2DS=/5B6-"G(L0-6-V7:9/Y;!X6"1@P2LH4MA$^2=7(Y+JLC>/7DP1
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M_3Q&G<SG%@S5L&)&E[B="FKPTIE<N7K0>CR5E54FAWGIBC:&O$Q?NJO>EF8
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MS3N]LFMIP.W:[<4GTN8_MAK<OKX:_'8Z:?/@].@W\O7>]=^?O/X?4$L#!!0
M   ( 'R"(ES=BS9A)@,  -\+   1    >G5R82TR,#(U,3(R.2YX<V2U5MMR
MVC 0?>],_T'U:\8VAEP*@6329)+2(4T'<G_IR+8@FLB2*\D!\O65;,M<#"[0
MEB=I]YRSN]*N3/MT$A'PAKC C'8LSZE9 -& A9B..M;=P#X;G'>[%C@]^?@!
MJ%_[DVV#2XQ(V (7++"[=,B.P7<8H1:X0A1Q*!D_!O>0)-K"+C%!')RS*"9(
M(N7((K7 H5/W@6UO('N/:,CX7;];R+Y(&8N6ZX['8X>R-SAF_%4X 8LV$QQ(
M*!-1J-4FM?RW&?T:BZ @[\&S@_'1I(\?1XA^3GJP\1P\P,-OV+\)WY_[>P]/
MKQ,9?3GR^P0VIHP\/?E'7Z>C6_ZX=[6/]F^RD&T1O* ( G475'0L75]>WKCA
M,#YRZ[6:YSY>]P8ISLJ K0G!]'45W&LVFV[J-= 2<N)S8J0;KG;[4*!"67EQ
M!1Y3(2$-%O"A+ CSX ,W<RY \4KH80;%!AJB)9Q @3-B;ZYR*'S]P  388\@
MC OP$ H_%<T="V#!91FHC,L@6TYC)%9",]<"X3WAL,#JC8^9;LD4Y-7K3357
M!$6(RDO&HPLTA E1>?Q*(,%#C$(+2,A'2.H>$S$,4+68Z5-(*5/MK$8JMVA;
M'&/5KX5!F?3]MC@CZ%8E#O1"S=/*"-KGGC/U(E@ AQTK6\YI&;40#3'%:>1\
M?#Q@ZV%)=)%JF3+;[C*XK)0(%-[0DW0=<R04/:VHIPPY/X=4<P-(@H3L1)WE
M5\7,[>8<2P=LIJB/AB"=OI;NDXXEL'[^K-SVPM&P8^DSM\UU_E1E.ZJ/#$1'
MJ)B^](Z63RH/;"0@#THJI==!B; 8<8E5,\\] 5GJ6&KZC[DP0,<1%G#_8>4$
M^MM6KBB(_,>2>UJ_7&O;71PLM5\>OK8JEW$):&F(JY[0[/'OL2"5JJ#HG6UX
MMC;97MUN>,Y$A+-,MTEB=@+;)6%X.R2QYB%?%5^L@^M%VD*;!EWS0:@,NI+C
M(B*%L>R<POSGXR]R2&6V2F+A.D/)72VA1??MFJ<N<7TZ?V*F>[%3$P0LH9)/
MMVF$>8K9['8;LP__9A=A\-DEZ/\"NX;=H0O*P5>U0-O-U-3R-U!+ P04
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M?-W8#>[MM,4W[I=[ ZO=\C]02P$"% ,4    " !\@B)<[C$-.KLA  !>NP
M$@              @ $     =&TR-3,Q,3(X9#%?.&LN:'1M4$L! A0#%
M  @ ?((B7,J1'HL?6P  HPD" !8              ( !ZR$  '1M,C4S,3$R
M.&0Q7V5X,3 M,2YH=&U02P$"% ,4    " !\@B)<T:V=VR46  !QD0  %@
M            @ $^?0  =&TR-3,Q,3(X9#%?97@Q,"TR+FAT;5!+ 0(4 Q0
M   ( 'R"(EP\4KO-=A4   &)   6              "  9>3  !T;3(U,S$Q
M,CAD,5]E>#$P+3,N:'1M4$L! A0#%     @ ?((B7-V+-F$F P  WPL  !$
M             ( !0:D  'IU<F$M,C R-3$R,CDN>'-D4$L! A0#%     @
M?((B7"#[UB3]"@  ?X8  !4              ( !EJP  'IU<F$M,C R-3$R
M,CE?;&%B+GAM;%!+ 0(4 Q0    ( 'R"(EQ%T 1]6 <  -)7   5
M      "  <:W  !Z=7)A+3(P,C4Q,C(Y7W!R92YX;6Q02P4&      < !P#1
) 0  4;\

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>tm2531128d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="zura-20251229.xsd" xlink:type="simple"/>
    <context id="AsOf2025-12-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855644</identifier>
        </entity>
        <period>
            <startDate>2025-12-29</startDate>
            <endDate>2025-12-29</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="AsOf2025-12-29" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-12-29" id="Fact000004">0001855644</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-12-29" id="Fact000011">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-12-29" id="Fact000012">2025-12-29</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-12-29" id="Fact000013">Zura Bio Limited</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-12-29" id="Fact000014">E9</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-12-29" id="Fact000015">001-40598</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-12-29" id="Fact000016">98-1725736</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-12-29" id="Fact000017">1489 W. Warm Springs Rd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-12-29" id="Fact000018">#110</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-12-29" id="Fact000019">Henderson</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-12-29" id="Fact000020">NV</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-12-29" id="Fact000021">89014</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-12-29" id="Fact000022">702</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-12-29" id="Fact000023">825-9872</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-12-29" id="Fact000024">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-12-29" id="Fact000025">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-12-29" id="Fact000026">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-12-29" id="Fact000027">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-12-29" id="Fact000028">Class A Ordinary Shares, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-12-29" id="Fact000029">ZURA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-12-29" id="Fact000030">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-12-29" id="Fact000031">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="AsOf2025-12-29" id="Fact000032">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
